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SUMMARY 
 
SUMMARY 
Transforming growth factor-β1 (TGF-β1) is a cytokine with pleiotropic functions within the 
immune system. Roles of TGF-β are the control of development, proliferation, survival, 
maintenance and differentiation of CD4+ T lymphocytes. TGF- signalling is strongly 
implicated in peripheral tolerance and maintenance of regulatory T (Treg) cells. TGF- was 
also reported to inhibit the terminal differentiation of CD4+ T cells into Th1 and Th2 subsets 
and it initiates Th17 cell polarization in a context-dependent manner. Constitutive abrogation 
of TGF- signalling in T cells has been reported to result in a rapidly lethal autoimmunity. 
To study the specific role of TGF- receptor II (TR2) in peripheral CD4+ T cells we generated 
CD4-CreERt2 mice and inducibly removed the receptor. The ablation of the TR2 was specific 
to CD4+ T cells leaving CD8+ T cells unaffected. Unexpectedly, induced deficiency of TR2 in 
peripheral CD4+ T cells did not result in autoimmunity or impaired tolerance. No signs of 
autoimmune inflammation were observed in tamiCD4TR2 mice even after thymectomy and 
long term tamoxifen treatment. Treg cells in our model retained their suppressive abilities in 
vitro and in vivo. Both, effector memory and Treg cells showed hyperproliferation while 
naive T cell numbers decreased through apoptosis. In contrast to previous reports no changes 
in NK and NKT cell compartment were observed in our model. In addition, the ablation of 
TGF- signalling in peripheral CD4+ T cell did not lead to their spontaneous differentiation 
into Th1 or Th2 subsets. 
We conclude that TGF- signalling in peripheral CD4+ T cells does not play a critical role in 
tolerance but acts as a negative regulator of Treg and effector memory T cell homeostasis. 
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ZUSAMMENFASSUNG 
 
ZUSAMMENFASSUNG 
Der Transforming growth factor-β1 (TGF-β1) ist ein Zytokin, das im Immunsystem 
vielfältige Funktionen ausübt. Er spielt eine entscheidende Rolle in der Kontrolle der 
Entwicklung, Proliferation, Erhaltung, Differenzierung und dem Überleben von CD4+ T-
Lymphozyten. Der TGF- Signalweg wurde mit der Erhaltung der peripheren Immuntoleranz 
sowie regulatorischen T-Zellen in Verbindung gebracht. Zudem wurde gezeigt, dass die 
Differenzierung in Th1 und Th2-Zellen von TGF- gehemmt wird, während er die Th17-
Entwicklung kontextabhängig induzieren kann. Nach der konstitutiven Inaktivierung des 
TGF- Signalweges in T-Zellen in Mäusen haben die Tiere eine rasch tödlich verlaufende 
Autoimmunkrankheit entwickelt. 
Um die Rolle des TGF- Rezeptor II (TR2) spezifisch in peripheren CD4+ T-Zellen zu 
untersuchen, haben wir CD4-CreERt2-Mäuse entwickelt, die es erlauben, den Rezeptor 
induziert zu entfernen. Die TR2-Ablation fand in diesem neuen System spezifisch in CD4+ T-
Zellen statt, wobei CD8+ T-Zellen unbeeinflusst blieben. Nach der Entfernung des TR2 in 
peripheren CD4+ T-Zellen konnten wir unerwarteterweise keine Entwicklung von 
Autoimmunität oder eine andersweitig beeinträchtigte Immuntoleranz feststellen. Auch nach 
Thymektomie und einer Langzeitbehandlung mit Tamoxifen zeigten die Mäuse keine 
Anzeichen von autoimmunen Entzündungsprozessen. Regulatorische T-Zellen blieben in 
ihren immunsuppressiven Eigenschaften nach der Unterbrechung des TGF- Signalweges in 
vitro und in vivo unverändert. Treg-Zellen und Effektor-Gedächtnis-T-Zellen zeigten eine 
Hyperproliferation, die Anzahl naiver T-Zellen hingegen nahm durch Apoptose ab. Im 
Gegensatz zu vorherigen Studien wurden keine Veränderungen in NK und NK T-Zellen 
festgestellt. Die Entfernung des TR2 in CD4+ T-Zellen hat auch nicht zu einer spontanen 
Differenzierung von naiven in Th1 oder Th2-Zellen geführt. 
11 
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Diese Ergebnisse lassen darauf schliessen, dass der TGF- Signalweg in peripheren CD4+ T-
Zellen keine entscheidende Rolle in der Erhaltung von Immuntoleranz spielt, sondern die 
Homöostase von regulatorischen und Effektor-Gedächtnis T-Zellen negativ reguliert. 
INTRODUCTION 
 
INTRODUCTION 
Transforming growth factor beta 1 (TGF-1) 
 The transforming growth factor-β (TGF-β) family consists of a large number of structurally 
and functionally related proteins involved in many biological processes during development, 
lineage commitment, proliferation, migration and survival of cells. The TGF- family 
contains two subfamilies of cytokines defined by sequence similarity and the specific 
signalling pathways that they activate. 
The TGF-β subfamily comprises three homologous isoforms in mammals: TGF-β1, TGF-β2 
and TGF-β3. They play a major role in control of cell cycle, proliferation and differentiation, 
as well as in immunosuppression, wound healing and production of extracellular matrix [1]. 
The three isoforms are encoded by three different genes and exert different functions. TGF-β1 
is the predominant form expressed by immune cells in mammals and crucial for the regulation 
of immune responses. In humans its major functions in angiogenesis and cancerogenesis have 
also been described [2-3]. The most crucial for immune system is TGF-1, the other two 
isoforms were so far not found to play a significant role [2, 4].  
Synthesis and signaling pathways 
TGF-β is synthesized as a precursor (pre-pro-protein) that is cleaved before secretion. The 
resulting TGF-β propeptide consists of the mature homodimer TGF-β and the non-covalently 
associated latency-associated peptide (LAP) [5-6]. This latent form can be either secreted 
directly or after binding the latent-TGF-β-binding-protein (LTBP), which play important role 
in targeting the TGF- to the extracellular matrix [5]. Extracellulary matrix mature TGF-β has 
to be liberated from the constraints of the associated proteins in order to bind to its receptor 
[1]. In this process plasmin and matrix proteinases, reactive oxygen species, the protein 
thrombospondin-1 and integrins αvβ6 and αvβ8 are involved [5, 7-8]. Both integrins bind to 
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an RGD motif in LAP but they act through different mechanisms. vβ6 mediated TGF-1 
activation occurs through the conformational changes in LAP whereas αvβ8-induced 
activation requires metaloproteinases. There are also studies showing that TGF- can be 
attached to the cell-surface and presented to the target cells [9-11]. 
The active form of a TGF- is a homodimer that is stabilized by hydrophobic interactions 
which are further strengthened by an intersubunit disulfide bridge [12-13]. The cytokine 
signals through the tetrameric complex of TGF-RI and TGF-RII each containing an 
intracellular serine/threonine kinase domain [1, 14-15]. 
The best elucidated signalling pathway used by TGF-β involves Smad proteins which deliver 
the signal into the nucleus [16-17]. By activation of TGF-βRI, the receptor is able to 
phosphorylate receptor-regulated Smads (R-Smad): Smad2 and Smad3. Phosphorylated R-
Smads form homotrimers and interact with Co-Smad4. Smads complexes can be transported 
to the nucleus via a non-canonical nuclear import pathway resulting from the ability of these 
proteins to interact with the components of the nuclear pore [18-19]. In the nucleus Smad 
complexes associate with other transcription factors, as by themselves they have low DNA 
binding affinity. Gene regulation by Smad proteins is then mediated through the recruitment 
of chromatin remodelling enzymes histone-acetyl transferases (HAT) e.g. CBP/p300, histone 
deacetylases (HDAC) e.g. Sno/Ski [20]. Also involved in TGF- signalling also involved is a 
third group of Smad protein, inhibitory Smads (I-Smad). Activated Smad2/3/4 complexes 
upregulate the expression of inhibitory Smad7.  In the cytoplasm Smad7 competes with 
Smad2 and 3 for binding to TGF-βRI and mediates the degradation of the receptor by E3 
ubiquitinase complexes [21-22]. 
Studies performed with cells deficient for Co-Smad4 or with mutated TGF-RI showed that 
other than Smad-mediated pathways for TGF- signalling exist [23-24] that involve the 
MAP-kinase cascades Erk, JNK p38 or activation of PI3K [25]. However activation of Erk 
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and JNK MAPK pathways can also result in phosporylation of Smad proteins. Thus, Smad-
dependent and Smad-independent pathways and the cross-talk of both determine the effect of 
TGF-β signalling on a cell. 
In the immune system, the action of TGF-β1 probably affects most immune-cell types as a 
result of broad distribution of the cognate receptor on these cells. It can be also synthesize by 
cells belonging to both innate and adaptive immune system. TGF-1 is also one of the most 
crucial cytokine in T cell biology. It affects T cell development, differentiation, proliferation 
and survival. The first study to show that TGF-β has a potent influence on the regulation of T 
cells was published by Kehrl et al. in 1986. They showed that human T cells were inhibited in 
IL-2 mediated proliferation by the presence of TGF-β in vitro. Furthermore, they noticed that 
activated T cells themselves were able to produce TGF-β [26]. Later studies showed the role 
of TGF- in the differentiation of T cells into effector cells and its role in central and 
peripheral tolerance. 
 
Acquired immunity and tolerance against self 
The immune system in the healthy individuals is balanced between driven tolerance against 
self-antigen and pathogen-driven immunity. Functional tolerance is based on the development 
of central and peripheral tolerance. The term central tolerance applies to the process of 
deletion of autoreactive lymphocytes during maturation in the central lymphoid organs, while 
peripheral tolerance applies to functional suppression in the periphery of autoreactive 
lymphocytes that have escaped elimination. 
Thymic development of the T cell and induction of central tolerance  
T cells are key players of adaptive immune system. The repertoire of different clones is able 
to respond to a seemingly limitless number of potential foreign antigens while simultaneously 
not responding to self-antigens expressed in the various tissues.  
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T cells develop from progenitors derived from pluripotent hematopoetic stem cells in the bone 
marrow [27] and migrate through the blood to the thymus where they mature. Developing T 
cells pass in the thymus through a series of distinct phases that are marked by the status of T-
cell receptor genes, expression of the T cell receptor (TCR) and by changes of the expression 
of cell surface proteins. Progenitors that enter to the thymus from the bone marrow are called 
double-negative (DN) because the co-receptors CD4 and CD8 are not expressed on their 
surface. In this stage thymocytes lack most of the markers characteristic for mature T cells 
and the TCR genes are not rearranged. Those cells give rise to either a minor population of  
or to a major of cells, only the latter will be in the focus of this thesis [28-29]. (Fig.I) 
Developing thymocytes undergo stringent selection processes that shape the T cell repertoire. 
The first checkpoint, called beta-selection ensures that only those DN thymocytes that have 
successfully rearranged their TCR locus progress to the CD4+CD8+ double positive stage 
(DP). Beta-selection is dependent on the signalling from the pre-T-cell receptor which consist 
of the -chain and a surrogate pre-T-cell receptor  chain called pT(for rev: [30-31]).  
(Fig.I) 
After progression to the DP stage and rearrangement of the TCR locus developing T cells 
interact with thymic stromal cells presenting peptides in the context of MHC. These 
interactions are necessary to shape the repertoire of T cells via processes called positive and 
negative selection. (for rev: [32-33]). It is still not completely understood how one receptor 
can drive opposite cellular response: differentiation, proliferation or apoptosis. The most 
recent publications showed that quantifiable variations in the affinity of a T cell receptor for a 
peptide–MHC complex can result in qualitatively different signals and thus determine 
thymocyte fate [34-35]. Failure of TCR to interact with self MHC-ligand complex at the 
appropriate level of affinity results in so-called death by neglect of the respective thymocytes. 
During this process an estimated 90 to 95% of thymocytes undergo apoptosis. [36].  
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Positive selection takes place in the cortical part of the thymus and the peptide-MHC 
complexes are presented by cTECs (thymic epithelial cells). These cells are able to generate 
MHC-bound peptides through unique pathways (for rev: [33]). Subsequent to positive 
selection and CD4 or CD8 lineage commitment thymocytes move to the medulla where they 
stay for four to five days [37]. During this period thymocytes interact with medullary APCs: 
thymic epithelial cells (mTEC) and dendritic cells (DCs) that present self-peptide in the 
context of MHC. T cells that recognize these peptides with an affinity that is too high undergo 
apoptosis, a process that is called negative selection and plays a key role in central tolerance. 
The ectopic expression of tissue-restricted antigens in the thymus is controlled in part by the 
autoimmune regulator (AIRE) gene [32, 38-39].  Targeted disruption of AIRE in the mouse 
leads to autoimmune inflammation in many organs [40]. A similar observation is made in 
human patients where the mutation in AIRE leads to development of autoimmune 
polyendrocrinopathy candidiasis ectodermal dystrophy (APECED) [41]. Numerous 
experiments showed that any disruption of mTEC development or medullary architecture 
result in development of systemic autoimmunity, which emphasize the role of medulla in 
induction of central tolerance.  
T cells that survived both processes, positive and negative selection differentiate into single 
positive CD4+ or CD8+ T cells depending on their respective abilities to bind invariant sites 
n MHCII and MHCI molecules and leave to the periphery as naïve T cells. o
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Fig. I Thymic T cell development  
T cells progenitor enters the thymus near the cortico-medullary junction.  DN thymocytes give 
rise to minor population of  T cells and a major population of  T cells. Thymocytes that 
successfully rearrange the  locus progress to the DP stage.  After rearrangement of the  locus 
DP thymocytes interact with self-MHC ligand complex. Failure of TCR to interact with such 
complexes on the certain level of affinity results in cell death. DP thymocytes undergo positive 
and negative selection which can result in apoptosis or development of CD4 and CD8 single 
positive T cells. 
 
 
 
 
 
TGF- signalling was shown to play a role in the thymic development of different T cell 
subsets. Early studies, performed in vitro, showed that TGF- was able to inhibit the 
proliferation of human thymocytes in response to IL-2 or IL-7 [42]. On the basis of another in 
vitro analysis a role of TGF- in the development of CD8+ T cells was proposed because this 
cytokine promoted CD8 expression in CD3- thymocytes [43]. Studies performed on fetal 
thymic organ cultures gave similar results [44]. TGF-1 was shown to be expressed in murine 
cortical epithelial cells [44] as well as human epithelial cells where TGF- regulates cytokine 
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expression by these cells directly affecting T cell development [45]. It was suggested that 
TGF-1 produced by TEC inhibits the progression of DN thymocytes to the DP stage [44].  
Experiments performed with TGF-1 deficient mice or conditional knockout of TGF- in 
immune cells allowed to confirm in vivo the observations based on in vitro studies. In the 
TGF-1 knockout strain which develop highly aggressive autoimmune disease total thymus 
cellularity was decreased. At the same time hyperplasia of the medulla and reduction of the 
thymic cortex were reported [46]. Later studies with the same model showed reduction in the 
DP thymocytes and increase in percentage of DN and CD4 SP compartments [47]. Studies 
using more specific mouse model that do not have TGF- receptor on cells of hematopoietic 
origin or on T cells resulted in partially contradictory observations. In TGF-RII deficiency in 
hematopoietic cells (by use of Mx1-cre) no aberrant thymic T cell development was observed, 
only CD8+ SP thymocytes showed increased proliferation [48]. In contrast, deletion of TGF-
RII in T cells (CD4 promoter) in one of the studies resulted in decreased TCRhiCD8+ SP T 
cells compartment and accumulation of DP thymocytes [49]. The studies using this model 
revealed an indispensable role of TGF- signaling in the thymic differentiation of NKT cells 
[49-50]. Furthermore, it was shown that TGF- directly orchestrate iNKT cell development 
directly through Smad 4, Tif-1g and the Tif-1g-Smad4 independent pathways [51]. 
Peripheral tolerance  
Despite stringent selection in the thymus even a healthy individual immune system contains 
self-reactive T cells that have escaped central tolerance. Thus, development of autoimmune 
response must be prevented by additional, peripheral mechanisms. 
Tolerogenic DCs are one of the primary mediators of peripheral tolerance [52-53]. They 
resemble immature DCs whereby the common features are the low expression of MHCII, 
CD40 and CD80/86 due to the absence of inflammatory molecules and “danger signals” [54]. 
The recognition of tissue-restricted antigen on tolerogenic mature DCs by T cells leads to 
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their functional inactivation and/or peripheral deletion in secondary lymphoid organs. DCs 
were also shown to contribute to the development of induced Treg cells (iTreg) and regulatory T 
cell that produce IL-10 in high amounts (Tr1)[55].  
The other components of peripheral tolerance are regulatory T cells. Those cells have the 
potential to suppress self-reactive lymphocytes that recognize antigens different from those 
recognized by Treg cells, a phenomenon called regulatory tolerance or dominant suppression. 
Absence or dysfunction of regulatory T cells lead to development of aggressive autoimmune 
diseases [56-57]. The protective role of regulatory T cells was shown in several autoimmune 
disease in mice like inflammatory bowel disease (IBD), SLE or experimental autoimmune 
encephalomyelitis (EAE) the mouse model for multiple sclerosis [58]. 
Regulatory T cells  
Regulatory T cells are a heterogeneous subpopulation of CD4+ T cells with different 
developmental origin which negatively control almost every adaptive immune response, 
either physiological or pathological. In 1995 a subset of CD4+ T cells with high expression of 
IL-2R (CD25) was found to have suppressive functions [59]. The main fraction of this cell 
type is called nTreg which is of thymic origin. However, naïve T cells in the periphery were 
also shown to be able to convert into cells with regulatory function. (Fig.II). These Foxp3+ 
regulatory T cells of peripheral origin are now termed induced or adaptive Treg (iTreg). It was 
reported that naïve T cells upon TCR and TGF- stimulation induce expression of Foxp3 and 
acquire suppressive functions [60]. The mechanism by which TGF-induces transcription of 
Foxp3 involves cooperation of the transcription factors STAT3 and NFAT at a Foxp3 gene 
enhancer element [61-62]. TGF- induction of Foxp3 expression was shown to be mediated 
by the recruitment of its downstream transcription factor Smad3 to a Foxp3 enhancer element 
[63]. TGF--induced Foxp3 expression is augmented in the presence of IL-2 which activates 
transcription factor STAT5 [64-65].  
20 
 
INTRODUCTION 
 
Other possible ways to generate these cells in vivo, including treatment of the mice with very 
little dose of antigens, has been described by several groups [66]. iTreg are especially present 
in gut and mesenteric LN, where CD103+ DCs are the key cell type involved in their 
induction [67]. GALT DCs have the ability to increase the gut homing receptor 47 integrin 
on T cells and additionally produce high amounts of retinal dehydrogenase which was shown 
to enhance iTreg generation [55, 68-69]. It is not clear which DC subset except DECT 205+ is 
responsible for the iTreg generation in other lymphoid organs. Apart from the dendritic cells, 
TGF- was also shown to play a the role in iTreg development in vivo. Abrogation of TGF- 
signalling in naïve T cells resulted in their decreased ability to convert into iTreg upon 
stimulation of low dose of antigen [70]. 
So-called Tr1 and Th3 regulatory T cells that do not express Foxp3 can also be induced in the 
periphery of naïve T cell. Tr1 cells can develop from CD4+ T cells after antigenic stimulation 
in the presence of IL-10, and they become IL-10 and TGF- producers [71-72]. Antigen-
specific TGF- producing Th3 cells were originally obtained from mice that were tolerant to 
orally administrated antigen. (for rev: [73]). Some recent studies show that Th3 express 
Foxp3 as well [74](Fig. II). 
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Fig.II Thymic and peripheral generation of regulatory T cells  
The peripheral pool of regulatory T cells comprises Foxp3+ nTreg of thymic origin and iTreg 
generated in the periphery as well as Foxp3- regulatory T cells (Tr1, Th3).  
 
 
 
Mechanisms of Treg-mediated suppression 
Foxp3+ regulatory T cells were shown to act through several distinct mechanisms on both T 
cells and antigen presenting cells (for rev:[75-76]). In vitro studies revealed a broad spectrum 
of molecules and processes that contribute to Treg suppressive activities. Yet, not all of them 
were shown to play a role in vivo. Regulatory T cells are able to inhibit T cell proliferation, 
activation and differentiation but they seem to also target APCs [77-78]. Treg cells were shown 
to mediate suppression of T cells by inhibiting the induction of IL-2 mRNA [79-81] or by 
competition of IL-2 consumption [82]. Regulatory T cells may also act on responding T cells 
through soluble factors like IL-10, TGF- or IL-35. Regulatory T cells that were not able to 
produce IL-35 were shown to be inefficient in IBD curing [83]. One other potential 
mechanism for Treg-mediated suppression of responder T cell is granzyme-mediated cytolysis 
of target cells [84]. Galectin-1, a member of a highly conserved family of -galactosidase 
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binding proteins, was also reported to be highly expressed on Treg and can interact with 
receptors on effector T cells, which results in cell cycle arrest or apoptosis [85]. 
One of the major functions of regulatory T cells is the inhibition of priming and 
differentiation of effector T cells. That is why antigen presenting cells are also the target for 
Treg cells. Among many mechanisms which are used by Treg cells to regulate APC function 
the CTLA-4 mediated suppression is considered to be the most crucial one. It has been 
proposed that the interaction of CTLA-4 on Tregs with CD80 and CD86 expressed by DC 
limits the capacity of these cells to stimulate naïve T cells through CD28. It was shown that 
the absence of CTLA-4 on Treg cells leads to the development of systemic autoimmune 
disease, which confirms the importance of CTLA-4 for proper Treg function [86]. A number of 
other mechanisms were proposed to be used by Tregs to decrease the co-stimulatory function 
of DCs. Among them, catalytic inactivation of extracellular ATP by CD39 expressed on Tregs 
was shown to be one of the most important one [87]. It was also shown that Treg cells can 
suppress DCs by strong binding of LAG-3 (CD223), a CD4 homolog to MHC-II expressed on 
dendritic cells, which leads to inhibition of their maturation and decrease of their co-
stimulatory functions [88].  
The role of TGF- for the Treg function is still not clear and data coming from in vitro and in 
vivo experiments are sometimes contradictive. In 2001 Nakamura and colleagues proposed 
the hypothesis that regulatory T cells carry bound TGF- on their surface. This membrane-
bound TGF- can be directly presented to target cells which would than locally convert it to 
the active form [89]. In their studies, blocking of TGF- signalling diminished Treg-mediated 
suppression. Similar studies performed by the group of Piccirillo [90] gave the opposite 
results. Up to now most of the studies performed with human and mouse Treg cells with anti-
TGF- antibodies in vitro failed to demonstrate decrease suppressive activity of regulatory T 
cells. More recent studies showed that Treg cells after strong TCR stimulation show on the  
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surface latency associated peptide (LAP) and very likely the latent form of TGF- [91-92].   
The observations coming from the in vivo studies also do not give the clear answer how TGF-
 contributes to the suppressive capacity of Treg cells. Transfer of TGF-1-/- splenocytes to 
Rag2-/- animals cause a disease that was exacerbated after depletion of TGF-1-/- Treg cells 
suggesting that TGF- is not essential for Treg suppression in vivo [93]. However, the 
regulatory T cells from TGF-1-/- or expressing dominant negative form of TR2 were not 
capable of inhibiting colitis induced by naïve T cell transfer [94]. Similar results were 
obtained in studies using the model with T cell specific deletion of TGF-1. The authors 
found that TGF-1-deficient Treg cells were defective in inhibiting colitis induced by 
transferred naïve T cells, and this defect was associated with the failure to inhibit naïve T cell 
differentiation into Th1 lineage [95]. 
Generation and homeostasis of natural regulatory T cells  
The term natural regulatory T cells (nTreg) applies nowadays to the CD4+CD25+Foxp3+ T 
cells that in mice constitute 5 to 10 % of total CD4+ T cells and represent a separate thymus-
derived lineage [96]. The transcription factor Foxp3 was shown to be essential for Treg 
development and function [97-99]. Nevertheless, recent studies rather suggest that Foxp3 is 
necessary to stabilize Treg function and their phenotype but that does not determine the cell 
fate decision that turns developing thymocytes into Treg cells [100-101]. However, the thymic 
development of regulatory T cells is still not completely understood. It is not clear which 
signal triggers the Foxp3 expression in the subpopulation of developing thymocytes (for rev: 
[102]) It has been suggested that for development of Treg cells a strong interaction between 
TCR and peptide-MHC complex is necessary [103]. Others showed that Treg are more 
resistant to apoptosis. This can be partially due to the high expression of GITR [104]. Co-
stimulatory molecules, especially CD28 and CD80/86, play an important role in Treg cell 
development [105]. One of the main features of Tregs is the high expression of IL-2 receptor 
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(CD25). The IL-2 signalling is important for survival and maintenance of regulatory T cells in 
medulla but its role in the generation of this CD4 T cell subset is dispensable [106]. This 
could be partially explained by compensatory IL-15 signalling since Treg cells also express 
also high level of IL-2R (CD122). 
The role of TGF- signaling in development of induced Treg cells is well established wherease 
its involvement in the generation of natural Tregs remains controversial. The analysis of very 
young heterozygous TGF-1-/- mice did not reveal differences in Foxp3+ thymocytes in 
comparison to control littermates [107]. Experiments performed with T cell-specific TR2-/- 
mouse model did not show affected development of natural regulatory T cells in the DP 
compartment prior to onsett of autoimmune disease in these mice [49-50]. Although in one of 
the studies [49] an increased population of Foxp3+ thymocytes in 2-week-old mice was 
reported. The latest reports using this mouse model showed increased thymic apoptosis of 
nTregs which correlated with down-regulated expression of anti-apoptotic protein Bcl-2 and 
increased expression of Bim [108]. The analysis of a mouse model with T cell-specific 
deletion of TGF-RI at different ages showed that thymic development of regulatory T cells 
was blocked in three to five day old mice but in mice older than one week lack of TGF-
signalling triggered their expansion [109]. Yet, the molecular mechanism by which TGF- 
signalling regulates early nTreg development is still unknown.  
TGF- is not only involved in the generation of regulatory T cells but is also thought to 
regulate their homeostasis and maintenance in the periphery. In secondary lymphoid organs in 
T cell-specific TR2-deficient mice the proportion of Foxp3+ T cells is decreasing over time. 
The BrdU labelling however showed their increased proliferation [49-50]. Also regulatory T 
cells from TR1 knockout mouse fail to survive in the periphery. In a study performed with 
DN-TR2 model the expansion of CD25+ CD4 T cells was shown, but without analysis of 
Foxp3 expression it remains unclear whether these cells were Treg or activated conventional T 
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cells [110]. In another report it was shown that T cell-produced TGF-1 is dispensable for the 
maintenance of Treg cells [95]. These findings suggest that Treg cells maintenance probably 
depends on TGF-1 produced by other cells than T cells. TGF- is also thought to regulate 
Foxp3 expression since the regulatory T cells that survived in the periphery of TGF-1 null 
mice had diminished expression of Foxp3 [107].  
Autoimmune inflammation 
Autoimmune diseases occur when immune cells initiate an attack against the body’s own 
tissues and organs. Under certain conditions, which very often remain unclear, the loss of 
peripheral tolerance to self-antigens leads to the expansion of self-reactive effector 
lymphocytes and development of inflammation in the tissues. Autoimmune diseases are 
usually classified into two categories: systemic and organ–specific. Systemic autoimmune 
diseases affect a variety of organs and usually involve a major humoral component. Systemic 
lupus erythematosus (SLE) and primary Sjörgen`s syndrome belong to this group. In tissue-
specific autoimmune diseases only one organ is targeted. Examples of this disease type are 
type 1 diabetes mellitus which is caused by immune attack on insulin-pancreatic  cells [111] 
or multiple sclerosis (MS) in which an immune response is directed against CNS antigens 
[112]. In these diseases cell-mediated autoimmunity is thought to play the major role. In 
addition to Th cells APCs are key players in the initiation phase and during progression of 
autoimmune disease; mainly by producing cytokine necessary for Th cells polarization. The 
cause of many autoimmune diseases is still not known but certain factors are thought to be 
favourable for the development of autoimmunity like chronic inflammation, infections with 
certain pathogens or genetic predispositions [113].  
Regulatory T cells play an important role in preventing autoimmune disease development. A 
spontaneous mutation in mouse in the Foxp3 gene (the scurfy mutation) leads to systemic 
autoimmune inflammation [98]. In human a single mutation in this gene results in X-linked 
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recessive autoimmune syndrome IPEX (immune dysregulation, polyendocrinopathy, 
enteropathy X-linked disease) [114]. Also, polymorphism of several genes that are controlled 
by Foxp3 and were shown to be important for Treg function, such as CTLA-4, CD25, IL-2 
are associated with increased susceptibility to autoimmune diseases including type 1 diabetes 
[115]. Moreover, the in vivo blocking of CTLA-4 was shown to exacerbate diabetes in NOD 
mice [116]. 
 
The role of TGF- signaling in T cells in the development and prevention of 
autoimmunity 
Mice deficient for TGF-1 were found to develop an early-onset multi-organ autoimmune 
disease leading to death by four weeks of age [117].These mice suffer from severe 
myocarditis, vasculits, hepatitis and lymphadenopathy. Deficiency of either of the two 
receptor subunits leads to an even more drastic phenotype with embryonic lethality between 
days E10.5 and E13.5 due to defects in vascularisation and hematopoesis [118-119]. 
Hematopoetic or T cell-specific expression of a dominant-negative receptor mutant or 
deficiency of either of the TGFRs or TGF-1 resulted in phenotypes resembling very much 
complete TGF1 deficiency with autoimmunity of varying severity. Mice with a dominant-
negative form of TGF-RII in T cells showed milder phenotype than TGF--/- animals. The 
disease onset was delay and the lesions were mostly found in mucosal organs such as lungs 
and colon [110, 120]. This was probably due to incomplete abrogation of TGF- signaling or 
change signaling in T cells. Mice with T cell specific deletion of TGF-RII suffered from 
nearly as severe disease as TGF-1-/- mice. They develop highly aggressive autoimmune 
disease that leads to death in the age of three to four [50] or five weeks [49]. Histological 
analysis of these mice reveled infiltrations of immune cells into multiple organs and tissues 
like stomach, liver, lung, pancreas and thyroid glands. The abrogation of TGF- signaling in 
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T cells was also found to lead to loss of B cell tolerance since antibodies against self-antigens 
were detected in the sera [49]. In addition mice suffered from lymphadenopathy, diffuse 
hepatocellular lipidosis with lymphocytic cholangiohepatitis, and lymphocytic myositis 
involving both the myocardium and skeletal muscles [50]. Infiltration of leukocytes to 
different organs was also reported in the mouse model in which the TGF-1 gene was 
disrupted in T cells [95, 121]. However, the disease onset was markedly delayed with the first 
syndromes appearing at the age of four month. The observed autoimmune phenotype in all of 
these transgenic mouse models was generally attributed to a defect in peripheral tolerance, 
especially in regulatory T cells and outgrowth of autoreactive T cell clones. 
TGF- was also shown to be involved in immune regulation in mouse models for human 
autoimmune diseases. Overexpression of TGF-1 in MRL/lpr mice that develop systemic 
autoimmune disease mimicking human SLE inhibits development of this syndrome [122]. In 
some SLE patient decreased production of TGF-1 was reported but it was not correlated 
with disease severity [123]. Systemic administration of TGF-1 inhibits the development of 
collagen- induced arthritis (CIA) in mice, which is the model of rheumatoid arthritis in human 
[124]. Several studies on the role of TGF-1 in type 1 diabetes mellitus were performed on 
NOD mice. In general overexpression of TGF-1 in either  or  cells inhibit the disease 
[125-127]. 
Experimental autoimmune encephalomyelitis (EAE), a model for the human disease multiple 
sclerosis (MS) (for rev: [128]), is another example of autoimmune inflammation in which 
TGF- was shown to play a role. Classical models of EAE are mainly driven by CD4+ T 
lymphocytes [129-131]. The disease can be divided into two phases: an initial T cell 
priming/activation phase and a subsequent recruitment and effector phase [132]. The effector 
phase involves migration of activated myelin specific T cells to the CNS, in which they cross 
the blood–brain barrier (BBB). Reactivated T cells in the brain initiate cascade of events, 
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including the secretion of chemokines that recruit predominantly macrophages to the site of 
inflammation.  
The majority of the studies performed on the EAE model show a beneficial role of TGF-1 in 
this disease. Administration of exogenous TGF-1 to mice was able to inhibit development of 
the EAE [133-135]. Treatment of mice with neutralising antibodies against TGF- enhanced 
the clinical severity of the disease [136]. Further beneficial effects for TGF-β were reported in 
the recovery phase of the EAE. Up-regulation of TGF-β along with other immunoregulatory 
cytokines as IL-10 and IL-4 was observed in recovering animals [137-138]. TGF-1 is also 
assosiated with the induction of oral tolerance to EAE antigens because treatment of mice 
with low dose MBP induced supressive Th3 cells that produce high amount of TGF-. A 
protective role of TGF-β on EAE development was also shown by a study with mice lacking 
TGF-β signalling in dendritic cells, as these animals were highly susceptible to the disease 
[139]. 
Several studies addressed the role of regulatory T cells in EAE. In general depletion of Treg 
cells before induction of the disease increased disease severity and mortality of the animals 
[140]. In the recovery phase of EAE an increased population of regulatory T cell expressing 
surface-bound TGF-β (in form of LAP) was reported, which suggested that remission is 
dependent on the immunoregulatory properties of TGF-β [9] (for rev: [141]). 
In contrast, TGF-β was also described to be involved in pro-inflammatory processes, as in 
promoting the differentiation of Th17 cells. It was reported that animals which expressed 
dnTGF-βRII in T cells lacked Th17 cells and developed significantly less severe EAE [142]. 
An important role for action of TGF-β in priming encephalitogenic Th17 cells was suggested 
as addition of neutralizing TGF-β antibodies in the immunization emulsion inhibited EAE 
development in wild type mice. In contrast to this local administration, systemic injection of 
anti-TGF-β did not block Th17 differentiation and disease induction. Also, in mice deficient 
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for T cell-produced TGF-β1 [95] IL-17 production was strongly reduced and animals were 
less susceptible to the disease. In contrast, a study investigating encephalitogenicity of Th17 
cells revealed that primed T cells restimulated in vitro in presence of TGF-β and IL-6 rather 
suppressed disease development whereas animals which received IL-23 driven T cells 
developed EAE [143]. TGF-β and IL-6 instead led to an increased expression of the 
immunoregulatory cytokine IL-10 by restimulated cells and thus prevented disease 
development. 
Peripheral T cells homeostasis and subsets of CD4+ T cells 
Homeostasis of naïve T cells 
The survival and the composition of the mature T cell pool are governed by complex 
homeostatic mechanisms. Naïve T cells, characterised by high expression of L-selectin 
(CD62L) and low expression of CD44 [144], hardly divide and their numbers remain 
relatively stable during the lifespan. The importance of TCR signalling for naïve T cell 
survival was shown by many groups. The lifespan of both CD4+ and CD8+ naïve T cells was 
shortened when they were deprived of contact with self-pMHC molecules [145-146]. Studies 
in which the TCR expression or TCR signalling was abrogated in mature T cells also showed 
a reduction in lifespan of naïve T cells [147-148]. However, these studies did not allow for 
concluding if the naïve T cells need the interaction with self-pMHC or if just the tonic 
signalling from TCR is sufficient. There are many evidences suggesting that naïve T cells 
have to home to secondary lymphoid organs to maintain a stable population size. Homing to 
the T cell zones in SLO is dependent on high expression of CD62L and CCR7 (CD197). 
Therefore, blocking or deletion of these molecules leads to decrease in naïve T cell lifespan 
[149]. The expression level of CD62L and CCR7 on naïve T cells was shown to be regulated 
by transcription factors Kruppel-like transcription factor KLF2 and FoxO1. The latter is also 
involved in regulation of IL-7r (CD127). IL-7 together with interleukins 2, 4, 7, 9, 15 and 21 
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belongs to the family of c-dependent cytokines, which use the c chain as a receptor subunit. 
The main source of IL-7 in secondary lymphoid organs is a subset of fibroblastic reticular 
cells (FRC) that are located in T cell zones. These cells produce also the chemokines CCL19 
and CCL21 which are the ligands for CCR7, thereby attracting naïve cells [149]. The survival 
signal induced by IL-7 binding is mediated through the activation of Jak1, Jak3 and Stat5a/b 
[150-151]. IL-7 and related cytokines promote cells survival by preventing the mitochondrial 
pathway of apoptosis [151]. 
In response to severe depletion of T cells naïve cells undergo spontaneous homeostatic 
proliferation. The process of slow lymphopenia-induced proliferation (LIP), also called 
homeostatic proliferation, allows the restoration of normal T cell level. Naïve T cells that 
undergo homeostatic proliferation acquire memory phenotype with high expression of CD44. 
LIP is mainly driven by interaction between TCR and pMCH and through IL-7 signalling. 
Nevertheless, co-stimulatory molecules such as CD24 (HSA) were also shown to play a role. 
Adoptive transfer of naïve T cells to the animal that chronically lymphopenic like RAG1-/- 
also leads to rapid homeostatic expansion that is drive by foreign antigens from commensal 
microflora and since it is greatly reduced in germfree environment [152].  
Homeostasis of memory T cells 
Memory T cells, in contrast to naïve cells, undergo intermittent cell division. Their longevity 
and division of both CD4 and CD8 memory T cells is independent of contact with pMHC and 
rely mostly on IL-7 and IL-15 [151, 153-155].  
Central memory T cells express CD62L and CCR7 which allows them to enter secondary 
lymphoid organs. Both, CD4+ and CD8+ memory T cells show high expression of CD127 but 
CD122 is only highly expressed on CD8+ memory T cells, which suggest that they are more 
dependent on IL-15 than CD4+ T cells. Recent studies show that expression of CD122 on T 
cells is regulated by two T-box transcription factors: T-bet and Eomesodermin (Eomes) [156]. 
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Unlike central memory, effector memory T cells are largely excluded from lymph nodes and 
instead accumulate in the spleen and in non-lymphoid peripheral organs. The homeostatic 
proliferation of these cells is probably mostly driven by IL-15 signalling but it is not clear 
whether they require interaction with pMHC (For rev: [151]). 
T helper subsets and their function 
CD4+ T cells play a critical role during adaptive immune response. They function through the 
secretion of specific cytokines and chemokines that provide signals for immune cells both of 
adaptive and innate immune system. CD4+ T cells recruit and activate CD8+ T cells, 
macrophages, neutrophils, and other effector cells to sites of infection and inflammation. 
They help B cells to produce antibodies, to undergo class switching and affinity maturation. 
They can also act directly on epithelial and mucosal cells during pathogen clearance (for rev.: 
[157-158]. 
The terminal differentiation of naïve CD4+ T cells to effector cells is directed by the cytokine 
milieu in which the T cells get activated when recognizing the antigen, although both the 
affinity of the peptide-Ag-TCR interaction and co-stimulatory signals influence the 
differentiation pathway as well.  
T helper 1 cells (Th1) 
In 1986, Mosmann et al. initially proposed a model whereby CD4+ T cells are subdivided into 
two independent subsets with distinct effector function. Their hypothesis suggested that Th 
cells can be segregated into a Th1 and Th2 subset on the basis of cytokine expression and 
bioactivities as well as helper function [159-160].  
Th 1 cells mediate immune response against intracellular pathogens. They also activate 
macrophages, neutrophils or NK cells [161]. They are generated from naïve T cell in the 
presence of IL-12 and IFN. IL-12 is secreted by APCs, mostly by DCs upon TLR activation 
[162]. IL-12 activates NK cells to produce IFN, which in turn activates Stat1 in responding T 
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cells and leads to upregulation of the master regulator of Th1 cells: T-bet [163]. This 
transcription factor drives the expression of IL-12 receptor 2 chain and IFN [158]. Later 
also IL-18R is upregulated and IL-18 was shown to act synergistically with IL-12 in 
inducing IFN. Except IFN, their signature cytokine, Th1 cells produce lymphotoxin  
(LT) and IL-2.  
For a long time the Th1 subset was considered to be the pathogenic T cells subset in the 
context of tissue-specific T cell-driven autoimmune disease and the Th2 subset was thought to 
be rather protective. This was based on the observations that Th1 cytokines are present in the 
inflammatory lesions and that they often correlate with disease severity [164]. Another hint 
came from a study in which EAE was induced by transfer of encephalitogenic Th1 cells [165-
166].  However, in stark contrast to this data, the generation and immunisation of mice 
deficient in Th1 cytokines such as IFNγ and TNFα demonstrated that they were not protected 
from autoimmune disease. Disease progression and severity of both EAE in TNFα-deficient 
mice was identical to that in wt mice, while IFNγ- and IFNγR- deficient mice were even 
hyper-susceptible to the disease [167-168]. In addition, deletion of Th2 cytokines generally 
did not affect the progression of autoimmune disease [169]. 
T helper 2 cells (Th2) 
Th2 cells mediate host defence against extracellular parasites including helminths. They 
provide help for B cells to produce IgE antibodies that are effective against parasites and 
worms. They were also shown to be involved in induction and persistence of asthma [170]. 
The polarization of Th2 cells is orchestrated by IL-4 and IL-2 [171]. Through signalling of 
IL-4 Stat6 is activated which leads to upregulation of the master transcription factor GATA-3 
[172]. GATA-3 has been reported to induce its own expression and is needed for expression 
of Th2 cytokines IL-4, IL-5, IL-10 and IL-13 [172-174]. Th2 cells are also able to produce 
IL-9 and IL-25.  
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T helper 17 cells (Th17)  
Th17 cells were shown to mediate immune response against extracellular bacteria and fungi 
[175]. Both IL-17A and IL-17F were shown to recruit and activate neutrophils during immune 
response against those infectious agents. Th17 cells are also connected with the development 
of autoimmune diseases. One of the paradoxical finding about the role of Th1 cells was the 
fact that neutralizing or deficiency of IL-12 had the opposite effect than deficiency of IFN on 
the induction of EAE. These studies were based on IL-12 p40-/- mice which are resistant to 
EAE. The explanation came later when it became clear that p40 can heterodimerise with p19 
to form another cytokine, IL-23 [176]. Mice deficient in IL-12p35 were surprisingly not 
resistant to MOG-induced EAE but actually showed an increased clinical severity [177-179].  
It was later shown that the mice deficient in the Il-23 subunit p19 were protected from EAE 
[180]. Due to the linkage between IL-23 and IL-17 expression a new T helper lineage, Th17, 
was proposed [181-182]. Studies with IL-17 knockout mice in our laboratory revealed that 
neither IL-17A nor IL-17F were essential for development of EAE, as these mice were 
susceptible and only showed minor differences in EAE course compared to control mice. 
Instead, another cytokine produced by Th cells with upregulated RORt, namely GM-CSF, 
was shown to play major role [183-184]; Codarri et al, submitted. 
In in vitro studies it was shown that TGF-β together with IL-6 induced the development of 
Th17 cells [185-187]. By signalling of these cytokines, RORγt is induced, which was found to 
be the master regulator for Th17 subset [188].  Another nuclear receptor ROR is also 
upregulated in Th17 cells but it is not crucial for IL-17 production [189]. Induction by TGF-β 
and IL-6 led to the up-regulation of IL-23 receptor and production of IL-21. IL-23 signalling 
was first considered to be important for Th17 development. Recently it is thought to be 
critical for the maintenance and restoration of Th17 cell functions [190]. Cytokines secreted 
by Th17 are IL-17A and F, IL-21 and IL-22. IL-21 was shown to play an important role in 
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positive feedback regulation for establishing IL-17 producing cells [191-192]. The cytokines 
that were reported to lead to full Th17 development, IL-6, IL-21 and IL-23, all signal through 
activation of STAT3 [193]. 
The role of TGF- signaling in differentiation and homeostasis of T helper cells  
In the majority of mouse with abrogated TGF- signalling in T cells, these cells undergo 
hyperproliferation, activation and differentiate into effector cells [49-50, 94, 110]. While 
effector and memory T cells were highly increased, naïve T cells were found to be strongly 
reduced. Both CD4 and CD8 T cells up-regulated activation markers such as CD44 and CD69 
and adhesion molecules like CD18 and CD11a and as well downregulated CD62L [49]. 
Furthermore, total numbers of CD4+ and CD8+ T cells were increased in the periphery [49-
50]. A BrdU incorporation assay showed increased proliferation of T cells in these models. In 
vitro studies suggested two mechanisms for TGF--mediated regulation of T-cell 
proliferation. TGF-β suppresses IL-2 production of activated T cells, thus inhibiting their 
proliferation [194].In addition TGF-β controls cell proliferation through regulation of the cell 
cycle regulators, both inhibitors and promoters [195]. It was shown that Smad3-dependent 
down-regulation of cdk4 may be essential for in the suppression of T cell proliferation by 
TGF- [196]. In the absence of TGF- produced by T cells these cells also undergo activation 
and hyperproliferation which suggests that T cells-produced TGF- is essential to control 
their homeostasis and maintenance [95]. 
TGF- was shown to be not only involved in the regulation of T cell proliferation but also in 
the control of their differentiation into effector phenotype. An enhanced differentiation of 
naïve T cells into effector T cells and increased cytokine production was observed in the 
absence or amelioration of TGF- signalling in T cells. TGF-was shown to be able to inhibit 
Th1 and Th2 cell differentiation in vitro through downregulation of the respective 
transcription factors T-bet and GATA-3 [197-199].  This inhibition was associated with the 
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TGF- blockade of TCR-induced activation of Itk kinase, calcium ion influx in T cell and the 
activation of transcription factor NFAT [200]. 
In Th2 development TGF-β suppressed IL-4 mediated STAT6 activation [198]. TGF-β had no 
inhibitory effect on IL-4 and IL-5 production on an established Th2 clone, thus suggesting 
that TGF-β signalling inhibits differentiation towards that subset, but not acquired effector 
functions [197]. TGF- together with IL-6 in vitro promotes the differentiation of T cells into 
Th17 cells [186-187]. The presence of TGF-β appeared to be critical for induction of Th17-
defining transcription factor RORγt [201]. In contrast, a recent study claimed that IL-6 and 
IL-23 together with IL-1β were able to induce full Th17 differentiation in the absence of 
TGF-β in vitro. 
Studies performed in vivo showed similar changes in T cell differentiation into effector 
phenotype. In mice expressing dnTGF-βRII under the CD4 promotor, an increased 
spontaneous differentiation of CD4+ T cells into both Th1 and Th2 cells was reported [197]. 
However, CD4+ T cells from mice with complete block of TGF- signalling in T cells 
differentiated spontaneously exclusively to Th1 cells [50] [49]. The T-bet mediated 
upregulation of CD122 expression in these cells was suggested by the authors to be 
responsible for better survival of Th1 cells in the investigated model [49]. In these transgenic 
animals also the development and maintenance of Th17 cell were investigated. In mice with 
TGF-βRII-deficient and TGF-β-deficient T cells a strongly reduced Th17 development was 
observed [187]. The overexpression of TGF-β in T cells enhanced Th17 development in vivo 
[185]. Recently, the induction of the transcription factor RORγt was shown to be Smad2/3 
independent, but Smad-dependent TGF-β signalling was still required for a complete Th17 
development [202]. Loss of negative regulator of TGF-β signalling Smad7 led to an enhanced 
Th17 differentiation whereas overexpression of Smad7 reduced this development [203]. 
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SPECIFIC AIMS  
 
The role of TGF-signallingfor CD4+ T cells was studied in many transgenic mouse models 
with T cells-specific deficiencies for TGF-1 and its signalling pathways. Constitutive 
abrogation of TGF- signalling in T cells has been reported to result in a rapidly lethal 
autoimmune syndrome in these mice. In addition lack of TGF- signalling during thymic 
development resulted in diminished population of CD8+, NK and regulatory T cells [49-51]. 
Due to impaired T cell development and lethal inflammation in mice with the constitutive 
abrogation of TGF- signalling in T cells, it was so far difficult to investigate influence of 
TGF- exclusively on CD4+ T cells. To address the role of TGF- signalling solely for 
mature CD4+ T cells, we wanted to circumvent the described impact on T cell development 
and the immediate hyperactivation of the immune system through the use of a novel 
tamoxifen –inducible CD4-CreERt2 strain which we crossed to the TGFbRIIfl/fl strain. 
 
The aims of this PhD thesis were: 
1. The analysis of the tamoxifen-inducible CD4Cre-ERt2 mouse strain in terms of Cre 
activity and specificity after crossing to two different reporter strains. 
2. Investigation of the role of TGF- signalling in peripheral CD4+ T cells for their 
homeostasis and maintenance by use of the CD4Cre-ERt2 TGF-RIIf/f (iCD4TR2) 
mouse strain. 
3. Assessment of the role of TGF- signalling for the differentiation of T helper cells by 
use of the iCD4TR2 mouse model. 
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MATERIAL AND METHODS 
Generation of the CD4-CreERt2 allele 
Targeting of the Cre-ERT2 fusion gene to the CD4 locus was achieved by replacing part of 
exon 2 including the start codon with the targeting vector pBluescript CD4-Cre19-ERT2 by 
homologous recombination in the C57BL/6 derived ES cell line Bruce4. Colonies were 
analyzed for homologous recombination events by Southern blot analysis of HindIII digested 
genomic ES cell DNA. Two positive clones were used for blastocyst injection. Probes were 
amplified with: 3’ probe: AAC TGC ACC GTG ACC CTG GAC CAG AAA AAG AA and 
GTA GGA GTG AAG GTC AGA GAC CAG GAC AAT AG, 5’ probe: CTT CAA ATA 
ATT AAC AAA ACA ACA AAA CCC TT and AAA AAC CAA AAC CAA CCC AAA 
CAA AAA ACA T 
 
Animal maintenance  
Tgfbr2fl/fl [48] were kindly provided by U. Malipiero and ROSA-EYFP mice [204] were 
kindly provided by A. Diefenbach, C57BL/6J (B6) mice were purchased from Charles River 
and congenic C57BL/6-CD45.1 and 2d2 bred in house. CD4CreERt2, CD4Cre, RAGE, 
TGFβRIIfl/fl, B6, B6-CD45.1, Rag1-/- , ROSA-EYFP mice were maintained in barrier and 
specific pathogen free facilities at the University of Zurich and handled in accordance with 
approved protocols under permits of the cantonal veterinary office. 
 
Genotyping 
DNA isolation 
Biopsies were incubated with tail lysis buffer plus Proteinase K (10 mg/ml) at 55°C for 4 h. 
After complete digestion the tube was centrifuged for 10 min at 13 000 rpm. To precipitate 
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genomic DNA the supernatant was decanted into isopropanol and centrifuged again for 10 
min at 13000 rpm. The remaining pellet was washed once with 70% ethanol and air dried for 
30 minutes. The DNA was solved in TE buffer and stored at 4°C. 
Primers for genotyping 
All oligonucleotides were purchased from Eurofins MWG Operon (Germany) 
Primer Sequence 
CD4CreERt2   A 5´-GCCAGCTCATTCCTCCCACTC-3´ 
CD4CreERt2   B 5´-CATGGGACTTTGGGCTTCTAGG-3´ 
CD4CreERt2   D 5´-CCCAACCAACAAGAGAGCTCAAGG-3´ 
TGF-βRIIfl/fl   3 5´-TATGGACTGGCTGCTTTTGTATTC-3´ 
TGF-βRIIfl/fl   4 5´-TGGGGATAGAGGTAGAAAGACATA-3´ 
2d2 Primer Vα3.2 5´-CCCGGGCAAGGCTCAGCCATGCTCCTG-3´ 
2d2 Primer Jα18 5´-GCGGCCGCAATTCCCAGAGACATCCCTCC-3´ 
ROSA 1 5´-AAGACCGCGAAGAGTTTGTC-3´ 
ROSA 2 5´-AAGGTCGCTCTGAGTTGTTAT-3´ 
ROSA 3 5´-GGAGCGGGAGAAATGGATATG-3´ 
EGFP 1 5´-CTATATCATGGCCGACAAGC- 3´ 
EGFP 2 5´ -ACTGGGTGCTCAGGTAGTGG- 3´ 
CD4Cre AG-CD4L6 5´ -CCC AAC CAA CAA GAG CTC AAG G- 3´ 
CD4Cre AG-Cre6 5´ -CCC AGA AAT GCC AGA TTA CG - 3´ 
 
Alternatively 2d2 mice were genotyped by use of TCR V and V chain specific antibodies: 
Vα3.2-PE and Vβ11-FITC.  
 
Animal experiments 
Tamoxifen application in vivo 
For tamoxifen (Sigma) application, the substance was first dissolved in 100% ethanol to 1 
g/ml, vortexed and mixed with olive oil to a final concentration of 100 mg/ml. The suspension 
was incubated at 56°C for 15 minutes and sonicated for 20 min. CD4CreERt2 x RAGE mice or 
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CD4CreERt2 x TR2fl/fl mice were force-fed with 5mg tamoxifen per day for five consecutive 
days. Day 7 after start of application is denoted 1 wk p.a.. For long term treatment mice were 
fed with tamoxifen citrate (Harlan) for 8 weeks at liberty.  
 
Bone marrow chimeras generation 
Bone marrow chimeras were generated by i.v. transfer of T cell-depleted bone marrow cells 
(1 x 107) into lethally irradiated (1100 rad) Rag1-/- mice. After transfer, mice were treated with 
antibiotics for 14 days; therefore 1 ml Borgal (24%) was added to 250 ml drinking water. 
Bottles with drinking water were changed every 7 days. Experiment with bone marrow 
chimeric mice started 5 to 6 weeks post reconstitution.  
 
Thymectomy  
Thymectomies were performed under Ketamine/Xylazine anaesthesia according to published 
procedures [205].  
 
In vivo proliferation 
For in vivo proliferation analysis BrdU (80mg/100ml) was added to drinking water and 
changed every second day for 7 days. After cell preparation intracellular staining with anti-
BrdU antibody (eBioscience) and Foxp3 Staining Buffer Set (eBioscience) followed by 
DNAse (Invitrogen) treatment for 1h at 37°C was performed. Samples were analyzed using 
FACS Canto II.  
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In vivo suppression assay (induction of colitis) 
For the in vivo suppression assay Rag1-/- mice were injected intraperitonelly with 4x105 
conventional T cells (CD45.1+) alone or in combination with 2x105 regulatory T cells 
(CD45.2+). Mice were weighed and assessed for clinical sings of colitis weekly and were 
killed 9 weeks after transfer. Colons were fixed in 4% formalin, paraffin-cut, and stained with 
hematoxylin and eosin.  
 
Adoptive transfer 
For the adoptive transfer assay Rag1-/- mice were injected intravenously with a 1:1 mixture of 
1x106 CD45.2+ and CD45.1+ T cells. Expansion of the T cells was assessed by staining of 
peripheral blood. 
 
Immunizations 
Immunization with KLH 
For immunizations, mice were injected subcutaneously with KLH (Sigma) together with CFA 
(100 µg per flank). After 10 days cells from draining lymph nodes and spleen were isolated. 
They were restimulated with 50µg/ml cognate antigen alone or together with 0.6 mg/ml anti-
CD28 or 50µg/ml OVA. Supernatants were collected for ELISA after 48 and 72h. 
Proliferation of the cells was determined by thymidine incorporation. 
Induction of active EAE 
For induction of EAE, mice were injected subcutaneously with MOG peptide (GenScript) 
(100 µg per flank) together with CFA (Difco Laboratories). At day 0 and 2 post immunization 
mice were injected with 100 µg pertusis toxin (Sigma). Animals were scored for clinical 
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symptoms of experimental autoimmune encephalomyelitis according to standard operating 
procedure as following:  
Score Clinics 
0  No detectable signs of EAE 
0.5 Distal limp tail 
1.0 Complete limp tail 
1.5 Limp tail and hind limb weakness 
2.0 Unilateral partial hind limb paralysis 
2.5 Bilateral partial hind limb paralysis 
3.0 Complete bilateral hind limb paralysis 
3.5 Complete bilateral hind limb paralysis and partial forelimb 
paralysis 
4.0 Moribund (mouse completely paralyzed) 
5.0 Dead 
 
Transfer of T cell and induction of EAE 
Mice were treated with tamoxifen as described above. 2 weeks p.a. lymphocytes were isolated 
and injected i.v. into RAG1-/- animals. Recipient mice were immunized with MOG peptide as 
described above. 
Passive EAE (Adoptive transfer of EAE) 
For adoptive transfer mice were treated with tamoxifen as described above. The animals were 
immunized with MOG (as described above); 100 µg Pertussis Toxin were injected i.p. on the 
day of immunization (day 0). Mice were euthanized 7 days after immunization and 
lymphocytes from spleen and draining lymph nodes were isolated. Cells were expanded by 
plating 7-8 million/ml in culture dishes (BD Falcon) together with 10 µg/ml MOG and 10 
ng/ml IL-23, and cultured for two days. RAG1-/- animals were injected i.p. with 20 million 
cells. 
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Histological Tissue Analyses  
Mice were euthanized with CO2, perfused with PBS and 4% paraformaldehyde in PBS. For 
histological analysis kidney, liver, heart, colon, small intestine were fixed in 4% 
paraformaldehyde in PBS, paraffin-embeded, cut into 30 µm thick sections and stained with 
hematoxylin-eosin according to standard procedures. For TUNEL staining 4 µm thick paraffin 
sections underwent TdT (terminyl deoxynucleodityl transferase, Roche Diagnostics)-mediated 
biotin-dUTP end nick labeling reaction for 30 min at 37°C. Digoxigenin was visualised by 
anti-Digoxigenin (Sigma) and Intense R HRP (Leica). The sections were counterstained with 
hematoxyline. 
 
Quantitative real time PCR analysis 
Different subsets of CD4+ T cells were isolated by FACS sorting and used for mRNA 
extraction (RNeasy mini kit, Qiagen).  mRNA was transcribed with M-MLV reverse 
transcriptase (Invitrogen). Quantitive RT-PCR was performed with MyIQ cycler (Biorad) 
using SyberGreen (Invitrogen), following primers were used:  
Primers for qRT-PCR Sequence 
TGF-β1 5´-GACGTCACTGGAGTTGTACC-3´ 
 5´-GGTTCATGTCATGGATGGTGC-3´ 
TGF-βRI 5´-CATTCACCACCGTGTGCCAAATGA-3´ 
 5´-ACCTGATCCAGACCCTGATGTTGTT-3´ 
TGF-βRII 5´-AACGACTTGACCTGTTGCCTGT-3´ 
 5´-CTTCCGGGGCCATGTATCTT-3´ 
RNA polymerase 2 5´-CTGGTCCTTCGAATCCGCATC-3´ 
 5´-GCTCGATACCCTGCAGGGTCA-3´ 
Cell culture 
All cells were handled under sterile conditions in a laminar flow bench. Cells were cultured at 
37°C in a 5 % CO2 atmosphere. Lymphocytes were cultured in RPMI 1640 medium, 
supplemented with 10 % FCS, 1 % Penicillin-Streptomycin and 0.5 % β-Mercaptoethanol.  
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In vitro proliferation and apoptosis assays  
Lymphocytes from LN and spleens were stained for CD4, CD44, CD62L, CD25, CD45RB 
and sorted by using FACS Aria.  The purity for each population was above 95 %. Cells were 
cultured in AIM-V medium (Invitrogen) supplemented with 0.05% 2-mercaptoethanol 
(Sigma) without stimulation. After 20 and 40h staining for Annexin V (BD Bioscience) and 
Topro3 or propidium iodide (1µg/ml) was performed. For CFSE-labelling cells from the 
spleen and lymph nodes were stained for 20 minutes in the dark with CFSE 
(carboxyfluorescein diacetate succinimidyl diester, 5 μM) washed in PBS and cultured in 
RPMI 1640 (Invitrogen) medium supplemented with 10% FCS, 1% penicillin-streptomycin, 
0.5% 2-mercaptoethanol. Cells were stimulated for 72h with 5 g/ml CD3 (2C11) and 5 
g/ml CD28 (N37).  
 
In vitro suppression assay 
Sorted conventional T cells (5 x 104) and Treg cells (in ratios according to figure legend) were 
cultured for 96 h in round-bottom plates along with anti-CD3 antibody (2C11, 2 μg/ml) and 
irradiated splenocytes in RPMI 1640 medium supplemented with 10% FCS, 1% penicillin-
streptomycin, 0.5% 2-mercaptoethanol. T cell proliferation was determined by thymidine 
incorporation and CFSE-labelling of Tconv cells as described above.  
 
In vitro T cell skewing conditions 
For skewing experiments lymph node cells and splenocytes were pooled and plated in 
complete RPMI in 24-well flat-bottom plates (BD Falcon) at a density of 4 million cells/ml 
per well. Cytokines and antibodies were added according to following protocols. Cells were 
cultured for 3-5 days. 
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Th1 condition  
αCD3 5 µg/ml 
αCD28 5 µg/ml 
IFNγ 20 ng/ml 
IL-12 20 ng/ml 
IL-2 10 ng/ml 
 
In order to perform intracellular staining on day 3 of 
culture, the cells were restimulated with 50 ng/ml PMA, 
500 ng/ml Ionomycin and 1 µl/ml BD GolgiPlug for 5 h. 
 
Th2 condition  
αCD3 5 µg/ml 
αIFNγ 10 µg/ml 
αIL-12 10 µg/ml 
IL-4 25 ng/ml 
IL-2 10 ng/ml 
 
On day 3 cells were split 1:2, fresh medium was added up 
to a total volume of 1 ml per well. IL-2 and IL-4 were 
added again. Cells were restimulated as described above 
and harvested for intracellular staining either day 4 or day 
5, supernatants were frozen at -20°C to perform ELISA 
for IL-5 and IL-10 production. 
 
Th17 condition  
αCD3 5 µg/ml 
αCD28 5 µg/ml 
αIFNγ 10 µg/ml 
TGF-β  10 ng/ml 
IL-6 20 ng/ml 
 
On day 3 cells were split 1:2, fresh medium was added up 
to a total volume of 1 ml per well. αIFNγ, TGF-β and IL-
6 was added again in the mentioned concentrations. 
Intracellular staining was performed either day 4 or 5 
after restimulation. 
 
 
For control conditions, cells were either cultured in pure complete RPMI 1640 or αCD3 and 
αCD28 was added accordingly: 
Control condition  
αCD3 5 µg/ml 
αCD28 5 µg/ml 
 
Cells were harvested after restimulation with PMA, 
Ionomycin and GolgiPlug as described above. 
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In order to delete the TGF-βRII in vitro 4-OH Tamoxifen was added in a final concentration 
of 1 µM. 
 
Flow Cytometric Analyses 
For flow cytometry the following fluorochrome conjugated antibodies were used: anti-CD3, 
anti-CD4 (L3T4), anti-CD8 (53-6.7), anti-CD11b, anti-CD11c, anti-CD19, anti-CD25, anti-
CD44, anti-45, anti-CD45.1, anti-CD45.2, anti-CD45RB, anti-CD49b, anti-CD62L, anti-
CD69, anti-CD122, anti-CD154, anti-GITR, anti-NK1.1, anti-IL2 all purchased from BD 
Biosciences, anti-TGF-RII from R&D, anti-Ly6A/E, anti-CD90.2 from BioLegend anti-
Foxp3, anti-BrdU, anti-NKp46 from eBiosciences. Staining for transcription factors Foxp3, 
Tbet and GATA3 was performed using Foxp3 Staining Buffer Set (eBiosciences) according 
to manufacturer’s protocol.  
For cytokine staining following fluorochrome conjugated antibodies were used: anti-
IFNanti-17A, anti-IL5, anti-GM-CSF from BD Biosciences; anti-IL4 from eBiosciences. 
For intracellular cytokine staining cells were stimulated for 4 to 6 h with 50 ng/ml PMA and 
500 ng/ml Ionomycin and the 1 µl/ml GolgiPlug (BD Bioscience)  
Samples were acquired using FACS CantoII (BD Biosciences) and analyzed with FlowJo 
software (Treestar). 
To enrich the CD4+ T cells population magnetic sorting was performed (CD4 T cell isolation 
kit, Milteney Biotech) according to manufacturer’s protocol.  
Treg cells and Tconv cells were sorted on a FACS Aria (BD Biosciences) on the basis of being 
CD4+CD45RBloCD25+ and CD4+CD45RBhiCD25- respectively. Naïve CD4 T cells were 
sorted on the basis of being CD4+CD44hiCD62Lllo, effector memory CD4+CD44loCD62Lhi, 
central memory CD4+CD44hiCD62Lhi and effector CD4+CD44loCD62Llo. 
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Enzyme-linked immunosorbant assay (ELISA) 
For the detection of serum antibody levels ELISA plates (PVC, BD Falcon) were coated with 
antibodies (anti-IgA, anti-IgG2a, anti-IgM) from Southern Biotech, for detection secondary 
antibodies (anti-mouse IgM, IgG, IgA peroxidase conjugated) from Sigma were used. The 
concentrations of cytokines in the culture supernatants were determined by ELISA (INF, IL-
4, GM-CSF, IL-10, and IL-2, IL-17 from BD Biosciences) according to manufacturer’s 
protocols.  
For detection of anti-dsDNA antibodies from the serum, ELISA plates (BD Falcon) were pre-
treated with 0.1% poly-L-lysine (Sigma) for 2 h, coated with 100 µg/ml DNA (Sigma) over 
night, blocked with 2% BSA for 2h. After washing with PBS anti-mouse IgG  chain HPR 
conjugated antibody (Sigma) was applied for 45 min and developed with stabilised 
chromogen (Invitrogen). 
 
ELISPOT 
For ELISPOT , cells from lymph nodes of KLH immunized mice (2x105 cells/well) were 
plated in complete RPMI medium containing 50 g/ml of KLH in 96-well plates (Millipore) 
coated with 7.5 g/ml of anti-IFN- (AN18; Mabtech) Plates were incubated at 37 °C in 5% 
CO2 for 20h. Then, 0.5 g/ml of biotin-conjugated anti-IFN- (R4-6A2; Mabtech) was added, 
followed by incubation at 25 °C for 2 h or 4 h, respectively. After plates were washed, 
streptavidin–alkaline phosphatase (Mabtech) was added, followed by incubation for 1 h at 25 
°C. Substrate solution BCIP/NBTplus (5-bromo-4-chloro-3-indolylphosphate–nitro blue 
tetrazolium; Biosource) was added to the wells, which were developed until distinct spots 
emerged. Plates were analyzed with an enzyme-linked immunospot reader (ImmunoSpot; 
CTL). 
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Immunofluorescent staining 
NIH3T3 cells were cultured on poly-d-lysine (Sigma) precoated glass slides. Cells were fixed 
with methanol (Fluka) for 10 minutes and permeabilized with 1% Triton X-100 (Sigma) for 
20 minutes. After blocking with 10% goat serum (Dako), cells were incubated over night with 
serum diluted 1:200 in 1% goat serum and 0.2% Triton X-100 (Sigma). Cells were incubated 
with goat anti-mouse IgG antibody AlexaFluor 546 conjugated (Invitrogen) for 45 min and 
the nuclei were counterstained with Hoechst 33342 (Invitrogen). Analysis was performed on 
40 mm microscope with CellM software.  
 
Statistical analysis  
P values were calculated with Student’s t-test using Prism software. P values of less than 0.05 
were considered significant. 
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RESULTS 
The role of TGF- signalling in T cells was studied in many transgenic mouse models. The 
studies performed with the strain in which TR2 was deleted from T cells already at the DP 
stage of thymic development [49-50] showed the role of TGF- in development, maintenance 
and differentiation of many CD4+ T cell subsets. However, in this model development of both 
CD4+ and CD8+ T cells is affected and the mice suffer from severe autoimmune disease 
which leads to their death at the age of few weeks. It is difficult to say if some changes 
observed in CD4+ T cell compartment in these mice are caused by sickness or if it is a 
primary effect of the absence of TGF- signalling. To more specifically address the role of 
TGF- signalling solely for mature CD4+ T cells, we therefore circumvented the described 
impact on T cell development and the immediate hyperactivation of the immune system 
through the generation of a CD4-CreERt2. 
. 
Generation and characterization of the CD4-CreERt2 strain 
The inducible CD4-CreERt2 knock-in strain was generated by Saskia Hemmers at the 
Institute for Genetics, University of Cologne. Tamoxifen-inducible Cre activity in this strain 
was expected to target mostly to CD4+ T cells (Fig. 1 a,b) [206]. Inducibility and specificity 
of Cre activity in the CD4CreERt2 stain was first assessed by crossing to the RAGE reporter 
strain featuring Cre-facilitated EGFP expression [207] and ROSA-EYFP strain [204]. 
Different doses and application routes of tamoxifen were tested including i.p injection and 
gavage. The highest EGFP expression was achieved after oral application of tamoxifen for 
five consecutive days. The reporter protein was detected in up to 70% of the peripheral CD4+ 
T cells. No EGFP signal was measured in CD8+ T cells, B lymphocytes or other CD4 
negative immune cells. Also in the absence of tamoxifen application EGFP was not detectable 
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in CD4+ T cells. In the double positive stage of T cell development hardly any recombination 
could be detected (Fig. 1c and data not shown).  
As anticipated, we also observed recombination in a small fraction of CD4+ splenic 
dendritic cells (DCs) and CD4+ positive lymphoid tissue inducer (Lti) cells (Fig. 1 d). To 
obtain a transgenic locus even closer to the physiological situation we next removed the 
neomycin resistance gene (Neo(R)) by in vivo FLP-mediated recombination ([208]. 
Unexpectedly, yet as described for another Cre transgenic mouse strain [209], removal of 
Neo(R) decreased Cre recombination frequency (Fig. 1 e) without improving specificity. In 
all further experiments we therefore used animals bearing the Neo(R)-containing allele. 
To achieve recombination in vitro 4-Hydroxytamoxifen, which is a metabolite of 
tamoxifen, was used. Different concentrations of this ligand were tested on unstimulated or 
CD4+ T cells activated with PMA/Ionomycin and Concanavalin A. The percentage of 
recombination upon 4-OH tamoxifen application was lower than after in vivo treatment with 
tamoxifen reaching 60% of activated CD4 T cells (Fig. 2a,b). Similar to in vivo treatment no 
recombination in CD8+ or non-T cell compartment was found (data not shown). No increase 
in cell death of stimulated T cells was observed after 4-OH tamoxifen treatment. 
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Fig. 1 Targeting strategy and primary analysis of the CD4CreERt2 system 
 
(a) Schematic map of the targeting strategy for the CD4 Locus. The Cre-ERT2 open reading frame 
and an FRT-flanked neomycin resistance gene were inserted into exon 2 of the CD4 locus of 
murine ES cells. HindIII restriction sites used for Southern blot analysis of the targeted ES cell are 
indicated. (b) Southern Blot screen of the targeted ES cells after digestion with HindIII and 
hybridization with the 5’ external probe and 3’ external probes. Homologous recombination is 
indicated by newly appearing 2.9 kb and 8.8 kb bands for the targeted allele in addition to the 10.6 
kb band for the WT allele. (c) Flow cytometric analysis of EGFP expression after in vivo 
administration of tamoxifen. CD4-CreERt2/RAGE mice were treated with tamoxifen orally for 5 
consecutive days and analysed at day 7 p.a.. These data are representative results of four 
independent experiments. (d) Flow cytometric analysis of EYFP expression after in vivo 
administration of tamoxifen. CD4-CreERt2/ROSA-EYFP mice were treated with tamoxifen orally 
for 5 consecutive days and analysed at day 7 p.a.. The gating scheme is indicated. These data are 
representative results of two independent experiments. (e) Flow cytometric analysis of EGFP 
expression after in vivo administration of tamoxifen. CD4-CreERt2Neo/RAGE mice were treated 
with tamoxifen orally for 5 consecutive days and analysed at day 7 p.a.. These data are 
representative results of two independent experiments 
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  Fig. 2 In vitro analysis of the CD4CreERt2 system in CD4CreERt2EGFP mice 
(a) The percentage of EGFP+ CD4 T cells at different time points after in vitro culture with 4-
hydroxytamoxifen. (b) The percentage of EGFP+ CD4+ T cells at day 4 of culture with different 
concentrations of 4-hydroxytamoxifen   
.  
 
 
 
 
Efficient ablation of TR2 from peripheral T cells without affecting T cell 
development  
Previous genetic analyses of the function of TGF-1 for T cells have either relied on 
germline gene deficiencies or involved conditional mutagenesis by use of the lck-cre, CD4-
cre, and MX-cre transgenes, thus resulting in gene ablation at the CD4-CD8- (double 
negative) and CD4+CD8+ (double positive) stages of thymic development and during 
hematopoiesis, respectively. Consequently, these models were characterized by alterations in 
thymic development of all T cell lineages [49-51] possibly causing the development of the 
observed autoimmune syndromes.  
Since we sought to investigate the role of TGF- signalling for peripheral T helper cells we 
then crossed the CD4-CreERt2 and a conditional TR2 (TR2f) allele [210] obtaining CD4-
CreERt2/TR2f/f (iCD4TR2). Throughout all experiments we used tamoxifen-treated CD4-
CreERt2/TR2f/+and TR2f/f as well as untreated iCD4TR2 mice as genetic and treatment 
controls. In none of the experiments we found differences between these control groups and 
unless indicated otherwise they are presented as one control. First, we tested ablation of TR2 
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from CD4+ T cells by tamoxifen treatment of iCD4TR2 mice for 5 days (herein called 
tamiCD4TR2) and, consistent with our observations using the reporter strain found surface 
TR2 to be reduced from 80% to 10% on blood CD4+ T cells 1 wk p.a. (Fig. 3a). Expression of 
TR2 by other cell types including CD8+ T cells within tamiCD4TR2 mice was unaffected and 
similar to that of control mice (Fig. 3a and data not shown). Target allele recombination was 
therefore efficient and restricted to CD4+ T cells. Next, we used quantitative RT-PCR to 
analyze the TR2 mRNA levels within T cell subsets 14 days after tamoxifen treatment. Sorted 
naïve (Tn, CD62Lhi and CD44lo), central memory (CD62Lhi and CD44hi), effector (CD62Llo 
and CD44lo), effector memory (Tefm, CD62Llo and CD44hi) and regulatory T cells (Treg, 
CD25+CD45RBhi) from tamiCD4TR2 mice had on average a 19-fold reduction of TR2 
mRNA levels, thus confirming successful and comparable deletion of the receptor (Fig. 3b) in 
the investigated T cell subpopulations. To confirm the physiological relevance of the 
observed TR2 deletion we performed an in vitro Th17 differentiation assay with cells from 
tamiTR2 and control animals. Absence of TR2 expression resulted in almost complete loss of 
Th17 and RORt expression, thus confirming efficient abrogation of TGF- signalling in 
CD4+ T cells (Fig. 3c). 
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Fig. 3 Efficient deletion of TR2 from peripheral CD4+ T cells. 
(a) Flow cytometric analysis of TR2 expression by CD4+ and CD8+ T cells from peripheral blood. 
These data are representative results of four independent experiments (b) Expression level of TR2 
mRNA in different FACS-sorted splenic CD4+ T cell subsets determined by quantitive RT-PCR. 
These data are representative results of three independent experiments. (c) Flow cytometric 
analysis of the expression of IL17 and RORt by CD4+ T cells after 4 days of culture in Th17 
skewing conditions.  
 
 
 
Because CD4 expression starts at the thymic DP stage we investigated the extent and 
consequences of TR2 ablation in the thymus. Analysis of thymic cellularity, size of the 
CD4+CD8+ (DP), CD4-CD8- (DN), CD4+ and CD8+ (SP) populations or expression of the 
markers CD5, CD24, CD62L, CD69 revealed no differences between experimental and 
control groups (Fig.4 and data not shown). The number and phenotype of thymic Treg cells 
was found to be unmodified as well (Fig. 4 and data not shown). Thus, in contrast to previous 
models used for analysis of TGF- function in T cells, our novel mouse strain allows the 
study of TGF- function in mature T cells without a disturbed thymic T cell development. 
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Fig. 4 Thymic development is not affected in tamiCD4TR2 mice 
Expression of CD4 and CD8 on thymocytes (upper panel), CD69 and CD24 markers on CD4+ SP 
thymocytes (middle panel), Foxp3 and CD25 on CD4+ SP thymocytes (lower panel) isolated from 
tamiCD4TR2 and control mice at 2 weeks p.a.. These data are representative results of three 
independent experiments. 
 
Peripheral abrogation of TR2 signalling in CD4+ T cells does not lead to 
autoimmunity 
Constitutive ablation of TGF- signalling during thymic development invariably results 
in a generalised and rapidly lethal autoimmune disorder [49-50]. We therefore investigated 
the effect of removal of TR2 from peripheral T cells by following clinical appearance, weight, 
autoantibodies, and histopathology in comparison to control animals. Unexpectedly and in 
contrast to all previously reported systems of ablation of TGF- signalling in T cells 
tamiCD4TR2 mice appeared healthy without any signs of autoimmunity two and four weeks 
p.a.. To exclude that the lack of autoimmune inflammation was due to the short tamoxifen 
treatment we performed an extended experiment in which we fed animals with tamoxifen 
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citrate for two months and followed them for three additional months. Similar to the short-
term treatment, we did not observe any signs of disease, neither clinically nor by weight loss 
(Fig. 5a). Because mild inflammation may not present clinically we performed 
histopathological analysis of liver, kidney, pancreas, heart and thyroid gland but could not 
detect any autoimmune infiltrates in any of these organs (data not shown). We then assessed 
whether the absence of TR2 on peripheral CD4+ T cells would lead to a secondary 
deregulation of B cell tolerance and to the consequent production of autoantibodies as 
observed in another model [49]. Yet neither by immunofluorescence staining of NIH 3T3 
cells with sera from tamiCD4TR2 mice treated with tamoxifen for five days or tamoxifen 
citrate for eight weeks nor by ELISA against dsDNA could we detect production of 
significant levels of autoantibodies (Fig. 5b, e). Thus, removal of TR2 from mature CD4+ T 
cells seems not to result in tolerance loss and autoimmunity. 
One possible explanation for this unexpected outcome is that thymic T cell output could 
compete with and dilute out CD4+ T cells lacking TR2 in our model. To exclude this we 
thymectomized iCD4TR2 and control mice one week before an 8-week tamoxifen citrate 
treatment. Even in the absence of newly developing thymic T cells, we again failed to observe 
any signs of autoimmune disease by clinical appearance and weight up to five months p.a. 
(Fig. 5c). Total serum antibody titers were indistinguishable between thymectomized 
tamiCD4TR2 and control animals and autoantibodies were undetectable in sera from both 
groups (Fig. 5d). Again, histopathology of various organs did not reveal any indications of 
immune infiltrates (Fig. 5f and data not shown). In conclusion and in contrast to previous 
reports [49-50, 110, 120], ablation of TR2 from peripheral T cells does not result in impaired 
T and B cell tolerance or autoimmunity. 
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Fig. 5 Lack of autoimmunity after abrogation of TR2 signalling in CD4 T cells in 
adult mice 
(a) iCD4TR2 and control mice were treated with tamoxifen citrate for two months and kept for 
another three months on normal diet. Body weight was monitored during whole period of 
experiment (mean ± SEM, 5 mice per group, representative data of two independent experiments). 
(b) ELISA for anti-dsDNA antibodies in sera from tamiCD4TR2 and control mice after 2, 4, 6 
weeks and 5 month p.a.; as positive control a serum from a fas-deficient mouse was used. (c) 
Repetition of the long term tamoxifen citrate treatment experiment as in a), but mice were 
thymectomized 1 week before tamoxifen treatment started (mean ± SEM, 3 mice per group, 
representative data of two independent experiments). (d) Anti-dsDNA ELISA as in b) but with 
sera from thymectomized mice after 4 month p.a. (e) Detection of antinuclear antibodies by 
immunofluorescent staining of NIH3T3 cells with sera from indicated mice. Representative 
micrographs are shown. The size bar indicates 40 µm (f) Representative micrographs of H&E-
stained tissue sections of indicated organs isolated from thymectomized tamiCD4TR2 or control 
mice after long tamoxifen treatment (40x) The size bar indicates 100 µm.  
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Non-conventional NK T cells are not generated upon peripheral removal 
of TR2 
Although absence of TGF- signaling in T cells was shown to block NK T cell development 
in the thymus [50-51], it also leads to the appearance of an aberrant non-conventional NK T 
cell population in the periphery. These CD8low or CD4+ cells contain most of the 
autoaggressive repertoire and do not recognize CD1/GalCer [50]. We therefore analysed 
whether such unconventional NK T cells were also found upon removal of TR2 from 
peripheral CD4+ T cells. In contrast to CD4-cre/TR2fl/fl mice we did not find any expansions 
of CD8low or CD4+ NK1.1+ T cells in tamiTR2 compared to control mice two and four weeks 
p.a. (Fig. 6). Even five months p.a. and after thymectomy these cells had not accumulated 
(Fig. 6). Thus, it seems that the pathogenic CD8low or CD4+ NK T cell populations develop 
only when TGF- signalling is compromised during thymic development.  
 
Fig. 6 Normal NK1.1 positive T cell subpopulations in tamiCD4TR2 mice 
Flow cytometric analysis of NK1.1 expression on splenic CD4+ and CD8+ T cells isolated from 
tamiCD4CreTR2 or control mice after different time points post tamoxifen administration. As a 
positive control 20 days old CD4CreTR2 pups were used.
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Dysregulated homeostasis of CD4+ T cell subpopulations in the absence of 
TGF- signalling 
 
All reported models of modified TGF- signalling in T cells have shown dysregulation of T 
cell activation, massively increased proliferation and concomitant decrease in the number of 
Tn cells [49-50]. When we compared tamiCD4TR2 to control mice at 2 and 4 wks p.a. we 
found CD4+ but not CD8+ T cell numbers in spleens and LNs slightly reduced (Fig. 7a). The 
total number and fraction of Tn cells in spleen were decreased 2 and 4 weeks p.a. (Fig. 7b,c) 
while an opposite effect in percentage and total numbers was observed for Tefm and Treg cell 
compartments with significant expansions 2 and 4 weeks p.a. (Fig. 7b,c). At all time points 
the percentages and total numbers of central memory and effector CD4+ T cells remained 
unaffected in tamiCD4TR2 mice (data not shown). Interestingly, six weeks p.a. the observed 
differences had altogether disappeared (Fig. 7b,c), indicating that the effect of TR2 removal 
on population sizes was transient.  
Differences in cell numbers result either from changed proliferation or apoptosis rates. To 
distinguish these possibilities we first assessed proliferation by BrdU incorporation. We found 
that the fraction of proliferating Tefm and Treg cells had increased sharply 2 weeks p.a. in 
tamiCD4TR2 compared to control animals while the fraction of cycling Tn and central 
memory CD4+ T cells remained unchanged (Fig. 7d and data not shown). 
To exclude thymic T cell replenishment we again performed thymectomy before removing 
TR2. The phenotype observed in not thymectomised tamiCD4TR2 mice now persisted at time 
point 6 weeks p.a, with significantly smaller CD4+ Tn and larger Tefm cells populations (Fig. 8 
a,b). Thymectomised tamiCD4TR2 and control mice were also analysed after longer period, 
at 20 weeks p.a. and the percentage and number of CD4+ Tn decreased even further. 
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Fig. 7 Increased proliferation of Tefm and Treg cells upon removal of TR2 
(a) Absolute number of CD4+ T cells in spleens and LN of tamiCD4TR2 and control mice 1, 2, 4 and 
6 weeks p.a. Mice were treated with tamoxifen for 5 consecutive days (mean ± SEM, 9 mice per 
group, analysed in three independent experiments). (b) Flow cytometric expression analysis of 
CD62L, CD44, CD25, Foxp3 on CD4+ splenic T cells of tamiCD4TR2 and control mice at 2 weeks 
p.a.. These data are representative results of three independent experiments. (c) The percentage of Tn, 
Tefm, and Treg cells in the spleen of tamiCD4TR2 and control mice (percentage out of CD4+ T cell, 
mean ± SEM, 9 mice per group, analysed in three independent experiments). (d) The percentages of 
BrdU+ Tefm and Treg CD4 T cells isolated from spleen of tamiCD4TR2 and control mice, gated on 
CD4+ T cells (mean ± SEM, 9 mice per group, analysed in three independent experiments). (e) The 
percentage of Tn, Tefm and Treg cells in the spleen of thymectomised tamiCD4TR2 and control mice 
(mean ± SEM, 9 mice per group, analysed in two independent experiments).  
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Although the Treg cell population in thymectomized tamiCD4TR2 mice appeared to be 
slightly enlarged at this time point, this was not statistically significant. The absolute numbers 
of Tn, Tefm, or Treg showed similar tendencies (Fig. 8 a,b). 
 
 
 
 
Fig. 8 Composition of CD4 T cell compartment in thymectomise mice 
(a) The percentage of Tn, Tefm, and Treg cells in the spleen of thymectomised tamiCD4TR2 and 
control mice (percentage out of CD4+ T cell, mean ± SEM, 9 mice per group, analysed in three 
independent experiments) (b) Absolute number of Tn, Tefm and Treg cells isolated from spleen of 
thymectomised tamiCD4RT2 and control (mean ± SEM, 9 mice per group, analysed in three 
independent experiments). 
 
 
 
 
 
 
We tested whether known factors governing T cell survival and proliferation were changed in 
the absence of TR2 and contributed to the increase proliferation of Tefm and Treg cells. No 
differences in expression of CD25 or IL-2 production between tamiCD4TR2 and control mice 
were found while a slight increase of CD122 (IL-2R) on CD4+ tamiCD4TR2 T cells was 
detected 2 week p.a. (Fig. 9a, b).  
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Next, to test for enhanced susceptibility to apoptosis by cells lacking TR2, it was removed 
from splenic CD4+ T cells in vitro. Annexin V and Topro-3 staining after 20 and 45h showed 
strongly increased incidence of apoptosis of cells lacking TR2 in comparison to control cells 
(Fig. 9c). Also, TUNEL staining performed on splenic sections revealed the profound 
augmentation of the presence of apoptotic cells in tamiCD4TR2 mice 2 weeks p.a. (Fig. 9d), 
correlating with the reduced number of Tn CD4+ T cells at this time point. In order to 
investigate whether certain subpopulations of CD4+ T cells upon removal of TR2 are more 
prone to apoptosis than the others, sorted Tefm, Treg and Tn were cultured with 4-
hydroxytamoxifen. Annexin-V staining after 20 and 40h of culture did not show a difference 
in apoptosis between TR2 deficient and respective control CD4+ T cell population (data not 
shown).  
The Bcl-2 protein, which is the member of pro-survival Bcl-2 family, was shown to be 
involved in the apoptosis of Treg cells in CD4CreTR2 mouse model [108]. This anti-
apoptoticprotein functions as a Bim antagonist. The expression of Bcl-2 in CD4+ T cells 
isolated from tamiCD4TR2 mice 2 weeks p.a. was slightly decreased compared to control 
cells (Fig. 9e) and no difference in Bcl-2 expression was observed in CD8+ T cells (Fig. 9e). 
The level of Bcl-2 was decreased in all CD4+ T cells subpopulations isolated from 
tamiCD4TR2 mice (data not shown). 
The cell death of CD4+ T cells from tamiCD4TR2 mice was further analysed in vitro on 
sorted population. Cells were isolated from iCD4TR2 mice and control mice and susequently 
sorted into Treg, Tn and Tefm. Cell death of the sorted population was more rapid and the 
incidence of apoptosis was much higher than T cell that were not isolated from total 
splenocytes (Fig. 9f). There was no difference in apoptosis between different CD4+ T cell 
subsets.  The experiment was repeated in a similar setup and sorted population were co-
cultured together with feeder cells and with or without IL-7. This increased the survival of 
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CD4+ T cells but there was no difference in incidence of apoptosis between TR2 deficient and 
control CD4+ T cells (data not shown). 
The observation that TGF--mediated suppression of proliferation affected only two T cell 
subpopulations prompted us to assess whether homeostatic regulation of these cell types 
comprises of a negative feedback loop involving autocrine production of TGF-1. To test this 
hypothesis we analysed whether TGF-1 was mainly produced by Treg and Tefm cells. 
However, no major differences between sorted T cell subpopulations could be detected by 
qRT-PCR analysis (Fig. 10) in the wild type situation (CD4-CreERt2/TGF-Rf/+). TGF-1 
expression seems to be also independent of presence or absence of TR2 (Fig. 10 a). Thus, we 
can exclude an autocrine suppressive function of TGF-1 for Treg and Tefm cells through a 
transcriptional negative feedback loop. Interestingly, we observed however that the mRNA 
levels of the other component of the TGF- receptor, TR1, were reduced specifically in the 
three T cell populations most-affected by TR2-deficiency (Fig. 10 b), which suggests a 
positive feedback loop for TR1 expression specifically in Tn, Tefm, and Treg cells. 
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Fig. 9 Cytokine signaling and apoptosis upon removal of TR2. 
(a) Flow cytometric analysis of IL-2 and CD25 expression by splenic CD4+ T cells isolated from 
tamiCD4TR2 and control mice. (b) Flow cytometric analysis of CD122 expression by splenic CD4+ 
T cells isolated from tamiCD4TR2 and control mice. Representative results of three independent 
experiments. (c) In vitro analysis of apoptosis induction. TamiCD4TR2 and control cells were 
cultured in AIM-V medium with or without tamoxifen. The ratio between AnnexinV positive CD4+ 
T cells that were tamoxifen-treated versus untreated is indicated (mean, 3 mice per group). 
Representative of three independent experiments. (d) Representative micrographs of TUNEL-
stained spleen sections from tamiCD4TR2 and control mice 2 weeks p.a. (40x) The size bar 
indicates 50 µm. Tunel positive cells were quantified by use of ImageJ software in five 
representative micrographs from each spleen. These data are representative of two independent 
experiments. (e)  Flow cytometric analysis of Bcl-2 expression by splenic CD4+ T cells isolated 
from tamiCD4TR2 and control mice. (f) In vitro analysis of apoptosis induction. Splenocytes from 
tamiCD4TR2 and control mice were sorted and cultured in AIM-V medium with or without 
tamoxifen for 72 hours 
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  Fig. 10 Expression of TGF-I and TGF-RII 
TGFR1 (a) and TGF1 (b) mRNA expression by the indicated CD4 T cell subpopulations 
FACS-sorted from spleen and LN (similar to Fig. 1) determined by quantitative RT-PCR at 2 
weeks p.a.  
 
 
 
 
The deregulation of Tefm and Treg cells lacking TR2 is cell-intrinsic 
To investigate whether the activation and proliferation of Treg and Tefm cells were an 
autochthonous result of absence of TR2 or whether deficient cells were acting in a paracrine 
fashion, we generated mixed bone marrow chimeras (WT-CD45.1+ and iCD4TR2 CD45.2+ 
experimental or CD4-CreERt2/TR2f/+ CD45.2+ control bone marrow) (Fig. 11a) that allowed 
us to determine whether the above-described phenotypic changes were restricted to the TR2-
deficient population. 2 weeks p.a. the activated phenotype of CD4+ T cells, defined by CD69, 
CD44, and CD62L was restricted to populations lacking the receptor (Fig. 11b and data not 
shown). Expansion of TR2-deficient (CD45.2+) Tefm and Treg cells was observed at 2 and 4 
weeks p. a. (Fig. 11 c,d,e). The deficient Tn cell compartment was reduced while the mutant 
effector and central memory T cells were unchanged. These observations were confirmed by 
BrdU analysis 2 weeks p.a. showing increased proliferative activity in the TR2-deficient Treg 
and Tefm cells but not in any other T cell population (Fig. 11f). Analysis of control chimeras 
showed no difference in percentages of cell types or incorporation of BrdU between the 
CD45.1+ and CD45.2+ populations. Thus, hyperactivation, increased proliferation of Tefm and 
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Treg cells and the cell death-induced reduction of the Tn cell compartment are cell-intrinsic 
consequences of TR2 ablation. 
TR2 deficient CD4+ T cells were also co-transferred together with wt CD45.1+ T cells into 
Rag-/- mice. Control animals obtained wt CD45.1+ CD4+ T cells and iCD4TR2 CD45.2+ T 
cells. Mutant CD4+ T cells expanded more than the co-transferred wt population. Also the 
CD45.1+ T cells in experimental mice expanded to a higher extent than the both CD4+ T cells 
populations in control animals. This suggests an additional extrinsic effect (Fig. 12a) that is 
IL-2 independent since neither IL-2 production nor CD25 expression were upregulated in 
experimental chimeras. 8 weeks after transfer only TR2-deficient CD4+ T cells expanded 
much more much more than wt CD4 T cells co-transferred with transgenic cells and control 
CD4+ T cells did (Fig. 12a). After 30 days post expansion TR2-deficient CD4 T cells 
produced significantly more IFN and together with co-transferred wt population less IL-2 
(Fig. 12b). At the end of experiment lymphocytes from spleen and mesenteric lymph nodes 
were analysed. As for the earlier time point expression of IFN was upregulated and the 
production of IL-2 downregulated in CD4+ TR2 deficient cells. The production of IL-17 by 
TR2-deficient CD4+ T cells was significantly lower (Fig. 12 c). 
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Fig. 11 The cellular changes are intrinsic to CD4+ T cells lacking TR2 
Rag1-/- mice were reconstituted with T cell-depleted bone marrow from wt CD45.1+ and CD45.2+ 
tamiCD4TR2 or iCD4TR2 in 1: 1 ratio and treated with tamoxifen for five consecutive days 5 
weeks post reconstitution (a) Scheme of the experimental setup (b) Flow cytometric analysis of 
CD69 expression on CD4+ splenic T cells isolated at 2 weeks p.a.. These data are representative 
results of three independent experiments. (c) The percentage of Tn and Tefm CD4+ T cells, cells 
isolated from LN (mean ± SEM, 10 mice per group, analysed in three independent experiments). 
(d) Flow cytometric analysis of the expression of Foxp3 and CD25 by CD4+ T cells isolated from 
LN at 2 weeks p.a  (e) The percentage of Treg cells within the lymph node CD4+ T cells of the 
indicated CD45.1+ or CD45.2+ bone marrow-derived cells (mean ± SEM, 10 mice per group, 
analysed in three independent experiments).  (f) The percentage of BrdU positive Tefm and Treg cells 
isolated from LNs (mean ± SEM, 10 mice per group, analysed in three independent experiments).  
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Fig. 12 Homeostatic expansion of TR2 deficient CD4+ T cells in lymphopenic host 
(a) Lymphocytes from tamiCD4TR2 or control iCD4TR2 mice were adoptively transferred (i.v) 
together with congenic CD45.1+ wt T cells. The percentage of CD4 T cells in peripheral blood 
(mean ± SEM, 5 mice per group). These are representative results of two independent experiments. 
(b) The percentage of IL-2 and INFg CD4 T cells in the spleen after 30 days post transfer (c) The 
percentage of IL-2, IL-17 and INFg CD4 T cells in the spleen (upper row) and mesenteric lymph 
nodes (lower row) et the end of experiment. 
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TR2 expression by Treg cells is irrelevant for their suppressive capacity in vitro 
and in vivo 
Key features of Treg cells are their expression of the transcription factor FoxP3 [98-99, 211] 
and of the surface proteins CTLA-4 and GITR (Tnfrsf18) [86, 212-213]. In the absence of 
TGF-1 a reduction of FoxP3 expression levels was reported in peripheral T cells but not 
thymocytes [107]. A first assessment of the impact of removal of TR2 from Treg cells showed 
FoxP3 levels to be unchanged in CD4+CD25+ cells between experimental and control animals 
at all analysed time points. CTLA-4 expression was found to be slightly upregulated while 
GITR levels remained the same in comparison to Treg cells of control animals (Fig. 13 a and 
data not shown). We next examined in vitro whether TR2-deficient Treg cells retained their 
ability to inhibit the proliferation of conventional wt T cells. Unexpectedly, we detected 
similar suppressive abilities by TR2-deficient and control Treg cells (Fig. 13 b,c). We then 
tested whether TR2-deficient Treg could also suppress mutant responder T cells, yet again with 
no change in Treg cell suppression (Fig. 13 d).  
Because of a seemingly opposing report [107] we performed an additional experiment 
and assessed suppression by mutant Treg cells in vivo through a colitis inhibition assay. TR2-
deficient or control Treg cells were co-transferred with CD4+ Tn cells into lymphopenic 
RAG1-deficient recipients. While transfer of Tn cells alone resulted in severe weight loss 
indicating colitis, the disease was similarly suppressed by co-transfer of Treg cells from 
tamiCD4TR2 and control animals (Fig. 13 e). Furthermore, also colon histopathology did not 
reveal any difference between suppression by TR2-deficient and WT Treg cells (Fig. 13 f). 
These results show that Treg cells neither require TGF- signalling for maintenance of Foxp3 
expression nor for exertion of their suppressive abilities in vitro and in vivo.  
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Fig. 13 Treg cells lacking TR2 are functional 
(a) Flow cytometric analysis of the expression of CTLA4 by Treg and Foxp3 by CD4+CD25+ T cells 
isolated from LN of tamiCD4TR2 , iCD4TR2 mice and mixed bone marrow chimeras. For  in vitro 
suppression assay sorted conventional CD45.1+ T cells were labelled with CFSE (b) or pulsed with 
thymidine for the last 24h of culture (c), stimulated with anti-CD3 and cocultured with sorted 
iCD4RT2 Treg cells or tamiCD4RT2 Treg cells (isolated 14 days p.a.) at various ratios. Analysis was 
performed after 96h. (c) Left panel: proliferation assessed as uptake of [3H]thymidine; right panel: 
percent suppression as mean ± SD (d) In vitro suppression assay: sorted conventional tamiCD4TR2 
T cells were stimulated with anti-CD3 and cocultured with sorted tamiCD4RT2 Treg cells at various 
ratios, pulsed with thymidine for last 24h. Analysis was performed after 96h (representative data of 
two independent experiment), (e) In vivo suppression assay: Development of colitis in Rag1–/– mice 
after adoptive transfer of conventional T cells alone or in combination with tamiCD4TR2 (mice 
treated for 5 days, cells isolated 1 week p.a.) Treg cells or iCD4TR2 Treg cells. Change in body 
weight after 8 weeks post transfer (mean, 3 mice per group, representative data of two independent 
experiments) (f) Representative micrographs of H&E-stained small intestine sections from colitis 
experiments as in (e) isolated from Rag1-/- 8 weeks after transfer of the indicated cells (20x).   
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The role of TGF- signalling in skewing of CD4+ T cells towards Th1, Th2 and 
Th17 cells 
In mice expressing dnTGF-βRII under the CD4 promotor, an increased spontaneous 
differentiation of CD4+ T cells into both Th1 and Th2 cells was reported [197]. However, 
CD4+ T cells from mice with complete block of TGF- signalling in T cells differentiated 
spontaneously exclusively into Th1 cells [50]. In the experiments performed with our 
inducible model we did not see changed differentiation of CD4+ T cells into certain Th 
lineages even after thymectomy and long period tamoxifen treatment.   
We wanted to test if there would be a difference in the expression of transcription factors or 
effector cytokines by TR2 deficient CD4 T cells in vitro in determined skewing conditions. 
To investigate the role of TGF-β signalling for T helper cell polarization, lymphocytes of 
tamiCD4TR2 mice were cultured under previously established conditions. Deletion of TR2 
receptor from CD4+ T cells was performed in vivo and cells isolated after 2 weeks p.a. were 
used for these experiments. 
For the in vitro differentiation into T helper 1 cells IFNγ and IL-12 were added [158, 163] and 
cells that had differentiated into Th1 cells were identified by production of the signature 
cytokine IFNγ as well as up-regulation of the transcription factor T-bet. Surprisingly no 
difference between TR2 deficient CD4 T cells and control CD4 T cells in expression of T-bet 
or IFN production was found (Fig.14 a). Production of other cytokines that are not 
characteristic for Th1 cells was also analysed in this skewing condition. The percentage of 
GM-CSF producing CD4+ T cells was significantly increased among TR2 deficient cells 
compared to control ones in both Th1 skewing condition and after stimulation with anti-CD3 
and anti-CD28 antibodies (Fig. 14 b).  
For the in vitro differentiation into T helper 2 cells, IL-4 and IL-2 were added to the cultures 
[171-172] and IFNγ and IL-12 signaling was inhibited by addition of the respective 
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antibodies. Analysis of CD4+ T cells from tamiCD4TR2 and control TR2 animals cultured 
under Th2 skewing conditions revealed no differences in GATA-3 and IL-4 expression 
between TR2-deficient and control cells (Fig. 15 a,b). Nevertheless, it seems that only after 
three days of culture the percentage of GATA-3 positive cells was lower within TR2 deficient 
CD4 T cell suggesting possible differences in the kinetics of Th2 cells development (data not 
shown). CD4 T cells isolated from tamiCDTR2 mice produced significantly higher amounts 
of IL-5 under Th2 skewing conditions and strong stimulation of TCR than control T helper 
cells (Fig. 15 c). No difference was detected between cultured tamiCD4TR2 cells and control 
TR2 cells in IL-10 expression (Fig. 15 c).  
For the in vitro generation of Th17 cells, TGF-β and IL-6 were added together with αIFNγ to 
induce expression of signature cytokines IL-17 and IL-21 [187-188]. In the absence of TR2 
CD4+ T cell produced significantly less IL-17 (Fig. 16). Instead the percentage of CD4+ T 
cells producing IFN under these skewing conditions was higher among the tamiCD4TR2 T 
lymphocytes (data not shown). 
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Fig. 14 In vitroTh1 skewing of tamiCD4TR2 and control CD4+ T cells 
tamiCD4TR2 and control TR2 cells were isolated 2 weeks post in vivo tamoxifen treatment and 
cultured in Th1 predisposing conditions and in αCD3/28 condition. (a): Flow cytometric analysis 
of IFNγ and T-bet expression by CD4+ T cells cultured in Th1 skewing conditions for 3 days. 
These data are representative results of 2 independent experiments. The plot represents the 
percentage of IFNγ and T-bet postive cells within CD4+ T cells under indicated conditions after 3 
days (mean ± SEM, 5 mice per group analysed in 2 experiments). (b) Flow cytometric analysis of 
IL-17 and GM-CSF expression by CD4+ T cells cultured in Th1 skewing conditions and 
CD3/CD28 condition. The plot represents the percentage of GM-CSF positive cells within CD4+ 
T cells under indicated conditions after 3 days (mean ± SEM, 5 mice per group analysed in 2 
experiments) 
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Fig. 15 In vitro Th2 skewing of tamiCD4TR2 and control CD4+ T cells 
tamiCD4TR2 and control TR2 cells were isolated 2 weeks post in vivo tamoxifen treatment and 
cultured in Th2 predisposing conditions and in αCD3/28 condition. (a)  Flow cytometric analysis 
of IL-4 expression by CD4+ T cells cultured under Th2 condition for 4 days. These are 
representative results of 3 animals analysed in one experiment. The plot represents the percentage 
of IL-4 positive CD4+ T cells (mean ± SEM, 3 mice per group analysed in one experiment). B: 
Flow cytometric analysis of GATA-3 expression by CD4+ T cells cultured under Th2 conditions 
for 5 days. The plots represent the percentage of GATA-3 positive CD4+ T cells on day 5 (mean ± 
SEM, 5 mice per group analysed in 2 experiments for day 5; 3 mice analysed in one experiment 
for day 4). (c) The amount of IL-5 and IL-10 in the culture supernatants measured by ELISA 
(mean± SEM; 5 mice analysed in 2 independent experiments; * P<0.05). 
 
 
 
 
 
 
Fig. 16 In vitro Th17 skewing of tamiCD4TR2 and control CD4+ T cells 
tamiCD4TR2 and control TR2 cells were isolated 2 weeks post in vivo tamoxifen treatment and 
cultured in Th17 predisposing conditions for 4 days. Flow cytimetric analysis of IL-17 and RORγt 
expression by CD4+ T cells. These are representative results of 3 animals per group analysed in 
one experiment. The plots represent IL-17 and RORγt positive or IL-17 positive T cells of 3 mice 
analysed in one experiment (mean± SEM).* P<0.05. 
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Altered T cell polarization in vivo in the absence of TGF signaling of CD4+ 
T cells 
 
In steady-state condition, without immunization, the profile of cytokines produced by TR2 
deficient CD4+ T cells is only slightly different from that of control T helper cells. The 
amount of produced Th2 cytokines measured ex vivo without anti-CD3/CD28 stimulation is 
so low that it does not allow describing the differences in the ability of tamiCD4TR2 and 
control Th cells of their expression (data not shown). IFN production measured ex vivo is 
upregulated in TR2 deficient CD4+ T cells but the difference is not as pronounced as 
described in a previously published model [49-50] (Fig. 17). Among the cytokines that were 
also upregulated is GM-CSF (Fig. 17). IL-17 is produced on a very low level and no 
difference in its expression could be observed. After stimulation of splenocytes with anti-
CD3/CD28 the total amount of IFN and GM-CSF produced were not changed, whereas the 
level of IL-17 was significantly reduced after three days of culture (Fig. 18). 
 
 
Fig. 17 Production of the cytokines in the steady state condition 
Spleens from tamiCD4TR2 and control mice were isolated 2 weeks p.a.. Cells were stimulated 
with PMA/Ionomycin for 4h. The plots represents the percentage of INF+, IL-17+ and GM-CSF+ 
CD4+ T cells  
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 Fig. 18 Production of the cytokines after in vitro stimulation 
Spleens from tamiCD4TR2 and control mice were isolated 2 weeks p.a.. Cells were 
stimulated with anti-CD3/CD28 for 48h and 72h. The plots represent the amount of 
cytokines in collected supernatants. 
 
 
 
Due to the fact that the amounts of Th2 or Th17 cytokines produced by CD4+ T cell in 
unimmunized mice are very low it is difficult to judge whether the mutated CD4+ T cells have 
a different ability to produce these cytokines than wt CD4+ T cells do. We did not observe in 
steady-state conditions that CD4+ T cells acquire a Th1 phenotype even after long tamoxifen 
treatment or treatment after thymectomy (data not shown). We therefore assessed the immune 
response in the presence and absence of TR2 on CD4+ T cells by immunizing tamiCD4TR2 
and control mice with the model antigen keyhole limpet hemocyanin (KLH). While we found 
that ten days post-vaccination the numbers of CD4+ T cells in the draining lymph nodes were 
identical between tamiCD4TR2 and control mice the composition of CD4+ T cell subset was 
changed. Similar to our observations in the steady-state the percentage of Treg and Tefm cells 
were increased in the lymph nodes from experimental animals and CD4+ T cells showed a 
more activated phenotype (data not shown). For analysis of proliferation and cytokine 
production we restimulated the lymphocytes in vitro with KLH and found that despite the 
increased numbers of Treg cell the CD4+ T cells from tamiCD4RT2 mice had increased 
proliferative abilities (Fig. 18 a). Also, TR2-deficient CD4+ T cells showed decreased 
production of the cytokines IL-17, GM-CSF, IL-4 and IL-10 which define different Th cell 
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subsets, after 48 and 72h post restimulation (Fig. 19 b). Unexpectedly, secretion of IFN and 
IL-2 by T cells from tamiCD4RT2 mice was identical to the one from control T cells after 48 
and 72 h, while the number of IFN-producing cells as measured by ELISOPT after 20h was 
higher for TR2-deficient T cells (Fig. 19 b and c).  
 
 
 
 
 
 
 
Fig. 19 Immune response after abrogation of TGF- signalling 
Mice were treated with tamoxifen for 5 consecutive days and immunized with KLH in CFA at day 
14 p.a.. Spleen and draining LN were isolated at day 24 p.a. (a) Proliferation measured as 
thymidine incorporation after a 72 h restimulation with 50 g/ml KLH,  (representative data of 
two independent experiments, 6 mice per group) (b) Cytokine production measured by ELISA 48 
and 72 h after restimulation with 50g/ml KLH or 50 g/ml KLH and anti-CD28 (IL-4 and GM-
CSF) (mean ± SEM, 12 mice per group analyzed in two independent experiments) (c) ELISPOT 
analyses of IFN- production by KLH-reactive lymphocytes restimulated for 20 h with 50 g/ml 
KLH (mean ± SEM, 6 mice per group, representative data of two independent experiments) 
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Due to the fact that in tamiCD4TR2 mice the Treg cells populations was significantly 
increased it is possible that the observed reduction in expression of certain cytokines are the 
result of a Treg suppression rather than an intrinsic disability of TR2-deficient CD4+  T cells to 
produce these cytokines. To overcome this caveat mixed bone marrow chimeric mice were 
generated in which CD45.2+ iCD4TR2 or control bone marrow were mixed in a 1: 4 ratio 
with wt CD45.1+ bone marrow. Unfortunately, the reconstitution in the spleen and lymph 
nodes after 5 weeks post transfer was 1:1 (CD45.2+ : CD45.1+) even in wt control chimeras 
which does not allow us to exclude the extrinsic effect of regulatory T cells. After KLH 
immunization of these chimeras the observed phenotype in terms of T cell activation 
resembles the one of the immunized non-chimeric mice (data not shown). To examine the 
cytokine production cells were restimulated with KLH and stained and analysed after 6 h. The 
data for cytokine expression were normalised to the percentages of effector cells within the 
certain subpopulation. There was no significant difference in the production of IFN between 
TR2-deficient and wt CD4+ T cells. Expression of IL-17 was significantly decreased in 
mutated compartment whereas GM-CSF production was increased, which confirm the data 
from previous in vitro experiments (Fig. 20) 
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Fig. 20 Immune response in mixed bone marrow chimeras after abrogation of TGF-
 signalling 
Percentages of cytokine producing cells were first normalized to their parent CD45.1+ and 
CD45.2+ population and than divided by the respective normalized number of effector and effector 
memory CD4+ T cells. The plots represents the percentages of IFN, GM-CSF and IL-17 positive 
CD4+ T cells among effector T cells in the total CD4+ T cell pool of the mouse (mean, 3 to 7 mice 
per group analysed in one experiment). 
Analysis of the role of TGF­ signaling in CD4 T cells in experimental 
autoimmune encephalomyelitis (EAE) 
The role of TGF- in EAE was studied in many mouse models including T cell-specific 
knockouts of TR2 or TGF-1 [95, 187]. In both models mice were less susceptible to EAE 
which was only correlated with the notion that CD4+ T cells in these mice produced less IL-
17. 
In our tamiCD4TR2 mice upon immunization with KLH we observed differences in 
production of IL-17, GM-CSF and some Th2 cytokines by TR-deficient CD4+ T cells. That is 
why we wanted to investigate the role of TGF- signaling in Th cells for the development and 
severity of EAE in tamiCD4TR2 mice. The same setup as for KLH immunization was 
applied. TamiCD4TR2 and control mice were immunized with MOG/CFA 2 weeks pa.. There 
was no difference in the day of EAE onset but the severity of disease was ameliorated (Fig. 
21 a, b). However, tamoxifen-treated control mice suffered from less severe EAE than oil-
treated controls (Fig. 21 a, b) which suggest tamoxifen side-effect affecting EAE severity. 
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Fig. 21 EAE course after abrogation of TGF- signalling in CD4+ T cells. 
tamiCD4TR2 and control mice tamoxifen or oil treated were immunized with MOG/CFA 2 weeks 
p.a. (a) disease course. (b) EAE disease incidence, mean time of disease onset and mean 
maximum clinical score of diseased mice.  
 
 
 
Therefore, another experimental setup was tested to investigate the effect of TR2 ablation on 
the development of EAE. The general approach to exclude a tamoxifen side-effect on EAE 
was to not perform tamoxifen treatment and MOG-immunization in the same mouse. To 
achieve this, lymphocytes from tamoxifen-treated CD4TR2 2d2 [214] and control mice were 
transferred into RAG1-/- recipients, followed by EAE induction after transfer. The percentage 
of naïve CD4+ T cells of 2d2 tamiCD4TR2 was reduced compared to 2d2 control TR2 
animals, as described for tamiCD4TR2 animals. The percentage of regulatory T cells was 
only slightly increased in 2d2 tamiCD4TR2 compared to 2d2 control TR2 animals (Fig. 22 a). 
All recipients were actively immunized with MOG/CFA four hours after cell transfer. All 
animals in both groups developed severe EAE. There was no difference in EAE onset or the 
severity of the disease between experimental and control mice (Fig. 22 b,c) 
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Fig. 22 Active EAE induction after transfer of tamiCD4TR42d2 and control cells. 
Donor CD4TR2 2d2 and control TR2 2d2 mice were treated with tamoxifen for 5 consecutive 
days. Cells for transfer were isolated 7 days after first day of tamoxifen treatment. Recipient 
RAG1-/- animals received 20 million cells. Recipient mice were immunized with MOG/CFA 4 
hours after cell transfer. (a) Flow cytometric analysis of CD44, CD62L, CD25 and Foxp3 
expression by transferred CD4+ T cells. (b) The graph represents the mean clinical EAE course 
over time post immunization (mean± SEM, 6 animals per group were analysed in one experiment). 
By day 28 p.i. all animals were dead. (c) EAE disease incidence, mean time of disease onset 
and mean maximum clinical score of diseased mice.  
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Tamoxifen-inducible Cre-ERt2 mouse models 
Several strategies were developed to achieve more precise spatial and temporal control of 
gene expression or modification in the mouse. The first available inducible Cre system was 
the Mx-Cre system [215] in which the Cre activity is regulated on a transcriptional level. The 
Cre recombinase is expressed under the control of an interferon-inducible promoter. The most 
popular nowadays is the tamoxifen inducible Cre-ERt2 system. It consists of the Cre 
recombinase which is fused to mutated human estrogen receptor (ER) ligand-binging domain 
[216-218]. The mutated ER domain binds the estrogen antagonist 4-hydroxytamoxifen but not 
the natural ligand –estradiol. Without ligand Cre-ERt2 stays in cytoplasm bound to heat 
shock protein (HSP90). After binding of the ligand to ER domain conformational changes 
occur and HSP90 dissociates from the fusion protein. Cre-ERt2 is trans-located to the nucleus 
where the Cre recombinase can bind to and recombine respective loxP sites. Several mice that 
express Cre-ERt2 under tissue-specific promoters were generated so far. In 2001 the 
tamoxifen inducible adipocytes specific mouse was reported in which Cre-ERt2 was expressed 
under the control of the adipocyte fatty acid binding protein (aP2) [219].  The Cre activity in 
this model was specific to adipocytes reaching 80% of recombination based on western blot 
analysis. The group of Hayashi reported a line that exhibited widespread expression of Cre-
ER [220] under a chimeric promoter consisting of the cytomegalovirus immediate-early 
enhancer and chicken-actin promoter/enhancer (CAGG). After tamoxifen application 
recombination was shown in embryos reaching more than 50%. Other tissue specific 
inducible mouse lines were generated in 2003 by the group of U. Suter [221]. The reported 
mice express Cre-ERt2 under the control of two different promoters that are specifically active 
in oligodendrocytes and/or Schwann cells. The Cre specificity and activity was tested in adult 
animals on the basis of -galactosidase expression. The percentage of recombination varies in 
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different parts of the brain from 75 to 90%. Another example of a tamoxifen-inducible mouse 
strain is the vil-Cre-ERt2 mouse in which Cre is expressed under the epithelium specific villin 
promoter [222]. No quantitative analysis was performed with this strain but -galactosidase 
activity was specific for the digestive tract epithelium. 
A transgenic mouse expressing Cre-ERt2 in the ventricular zone of the developing nervous 
system under the control of the nestin promoter and enhancer (Nes-CreERt2) was published in 
2006 [223]. After crossing this mouse to the EGFP reporter strain the Cre-mediated 
recombination upon tamoxifen treatment was detected in 10-50 % of neuronal progenitors. A 
similar Cre activity was obtained in a model where CRe-ERt2 was expressed under a 
promoter specific for dorsal root ganglion (DRG) neurons [224]. 
So far there is only one tamoxifen -inducible Cre strain specific for hematopoietic cells 
reported - the Em/PSV40 Cre–EBD mouse [225]. In this case the immunoglobulin heavy 
chain enhancer (E) was combined with the SV40 early minimal promoter to direct transgene 
expression exclusively to B lymphocytes. The maximal recombination that was observed in 
this model reached 65%. As Cre was not expressed in all IgM+ cells, the 65% maximum of 
observed recombination reflects >80% recombination in Cre-expressing cells. 
Our CD4Cre-ERt2 mouse is the first tamoxifen inducible T cell specific mouse model. The 
Cre-ERt2 expression is driven by the CD4 promoter which is active from the DP stage on in T 
cell development. To judge Cre specificity and activity we crossed the mice to two different 
reporter mouse strains: RAGE-EGFP [207] and ROSA-EYFP [204]. After tamoxifen 
treatment of adult animals we achieved 70 to 80% of recombination solely in CD4+ T cells 
which in comparison to other inducible mice is very efficient. After the treatment of adult 
mice we did not observe any Cre activity in CD8+ T cells or other cells types that do not 
express CD4. As expected some recombination was detected in CD4-expressing splenic DC 
subsets and NKp46+ LTis.  There was also no EGFP+ or EYFP+ CD4+ T cells present before 
tamoxifen application which means that the construct is very tight. By crossing CD4-CreERt2 
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mouse with a Flp deleter mouse [208], Flp-mediated recombination was used to excise the 
neomycin selection cassette. Astonishingly, the percentage of recombination after removing 
neomycin was much lower than with the neomycin cassette. The influence of the neomycin 
selection cassette on the expression level was reported before [209]. Therefore for further 
experiments only the strain with neomycin cassette was used.  
Different ways and doses of tamoxifen application were tested in our strain. We did not 
observe any obvious changes in the behavior, feeding, or appearance of the mice even after 
the long term, 60 days treatment. Tamoxifen and 4-OH tamoxifen were also tested for the in 
vitro recombination of target alleles in CD4+ T cells. In contrast to some reports we did not 
observe an increased in the cell death of activated cells after co-culture of splenocytes with 
these ERt2 ligands.  
After testing the Cre specificity and efficiency in CD4Cre-ERt2 mouse crossed to reporter 
strains, our new mouse was crossed to TGF-RII strain [210]. Due to technical problems with 
TR2 surface staining it is difficult to exactly calculate the percentage of CD4+ T cells that 
have deleted the receptor after tamoxifen treatment. We observed a reduction from 80% to 
10% of CD4+ T cells expressing TR2 which means that the percent of recombination with this 
target was similar to one achieved with the RAGE EGFP reporter strain. In addition to the 
TR2 surface staining the analysis on mRNA level was performed. In tamiCD4TR2 animals 
the expression level of TR2 was reduced to an average 5% of control TR2 animals, which is 
very efficient deletion as for an inducible system. We also performed functional assays in 
vitro to show that CD4+ T cells from tamiCD4TR2 mice do not respond to TGF-signaling. 
TGF-together with IL- 6 is known to induce the expression of IL-17 and ROR [185]. In 
contrast to control CD4+ T cells, tamiCD4+ T cells did not produce any IL-17 upon 
stimulation with IL-6 and TGF-which confirms the efficient abrogation of TGF- signaling 
in our model.  
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The role of TGF- in central tolerance 
The pleiotropic nature of the TGF- family members has made it extremely challenging to 
unravel the role of these messengers within individual functional systems. The analysis of 
general and T cell-specific gene-deficiencies for TGF-1 and its signalling pathways have 
invariably revealed severe autoimmune phenotypes, some with rapid death shortly after birth 
[49-50, 95, 120-121, 197, 210]. These observations resulted in the notion of TGF- being 
required for maintenance or establishment of T cell tolerance. Also, T cell-restricted double 
deficiency of Smad 2 and Smad 3, members of the canonical TGF- signalling cascade, but 
not their single deficiencies, led to severe inflammation in various organs followed by death 
[202, 226-227]. Yet, because gene ablation in all these systems took place or was present 
during thymic development it cannot be excluded that the observed immune deregulation was 
a consequence of T cell development in the absence of TGF- signals. To overcome this 
caveat and analyse the role of TGF- signaling only in post-thymic CD4+ T cell we treated 
adult iCD4TR2 animals with tamoxifen. Since there was no change in expression of TR2 in 
CD8+ T cells we can assume that recombination took place only in the periphery not in the DP 
stage of thymic development. We did not see any changes in thymus in terms of cellularity, 
CD4+ to CD8+ T cell ratio or expression of the markers like CD5, CD24 and CD69. Deletion 
of TGF-RII in T cells in one of the studies resulted in decreased TCRhiCD8+ SP T cells 
compartment and accumulation of DP thymocytes [49]. In contrast to other reports the nTreg 
population in the thymus was not increased [49, 109]. 
TGF- was reported to be involved in the development of the iNKT (invariant NKT cells), a 
subclass of NKT cells ([49, 51]. In our studies we did not observe a difference in the number 
of NKT cells. Recent studies showed the role of TGF- in the development of yet another 
subpopulation of T cells: CD8+ intestinal intraepithelial lymphocytes (IELs) [228]. The 
development pathway of this population was under debate but now they are considered to be 
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of thymic origin. TGF- was found to inhibit the apoptosis of the precursors of CD8+ IELs 
and also to induce and maintain CD8expression in these cells. Still is not clear if diminished 
number of CD8 IELs in the intestine in CD4Cre TGF-RI mice can contribute to 
development of autoimmunity.  The authors showed as well that TGF-promote expression 
of CD8 in thymocytes by diminishing Th-POK transcription factor.  
It is tempting to speculate that negative selection in the thymus depends on TGF- 
signalling, leading to emigration of autoreactive clones in its absence. Indeed, a recent study 
found exaggerated negative selection in absence of TR2 [108], an outcome that is in line with 
decreased but not increased autoimmunity. We did not study in our model in detail thymic 
development by crossing iCD4TR2 mice to RIPmOVA mice, so we cannot exclude that in 
our model negative selection is affected to some extent. 
We are currently investigating if the ablation of TGF- signaling from CD4+ T cells in 
our model during the thymic development is causing autoimmune inflammation. To answer 
this question we generated bone marrow chimeras with iCD4TR2 and control bone marrow. 
The recipient mice were treated with tamoxifen before reconstitution and after such that the 
CD4+ T cells had abrogated TGF- signaling already from the DP stage of development. In 
the very first experiment the experimental chimeras develop disease four weeks post 
reconstitution. The changes in CD4+ T cell compartment, infiltration of the leukocytes to the 
organs and presence of autoantibodies in these mice are currently investigated. 
To summaries, so far in our tamiCD4TR2 mouse we did not observe any changes in thymic 
development of any CD4+ T cell subset after treatment of tamoxifen adult animals. 
The role of TGF- in peripheral tolerance and control of autoimmunity 
Despite efficient TR2 gene ablation in mature CD4+ T cells in tamiCD4TR2 mice we 
did not observe any clinical or immunological manifestations of autoimmunity in our model, 
in contrast to all other models of modified TGF- signalling in T lymphocytes [49-50, 109-
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110, 120, 210]. Even when we employed more stringent experimental setups, including 
thymectomy and long-term tamoxifen application for 60 days, no indications of tolerance loss 
like the presence of autoantibodies could be found. We are confident that the ~10–20% 
unmodified cells remaining in our model are not the cause for the observed lack of 
autoimmunity because two groups have shown independently that chimeras with 50% CD4-
cre/TR2f/f and WT bone marrow still develop the lethal autoimmune syndrome[49 , 50]. Even 
upon adoptive transfer of TR2-deficient cells into WT recipients vigorous proliferation of 
these cells within the otherwise normal environment was observed [49]. Since we did not 
detect a depletion of the Treg cell compartment similar to the other systems [49-50, 107] the 
lack of autoimmunity could have been attributed to suppression by these cells. Yet, again it 
has been shown by complete repopulation of the Treg cell compartment through transfer of 
WT Treg cells into 2 days old CD4-cre/TR2f/f mice that Treg cells cannot prevent or ameliorate 
the autoimmune syndrome [49]. Thus, we are confident that the incomplete gene deletion 
does not account for the divergent phenotype between the constitutive and our inducible 
model. Autoimmunity has, however, been observed in another setup of peripheral TR2 
ablation in which in vitro TAT-Cre treatment was followed by adoptive transfer into RAG-
deficient mice [50], thus seemingly contradicting our data. Yet, activation and expansion of 
the transferred T cells followed by development of autoimmunity may in this case be the 
result of naïve T cells being transferred into lymphopenic hosts [229]. Two explanations 
could account for the absence of autoimmunity after peripheral TR2 ablation, namely 
unmodified T cell development or restriction of the gene modification to CD4+ T cells. As 
mentioned before, it is very unlikely that in our model T cell development and selection 
processes in the thymus are affected.  
One report placed the pathogenic activity of TR2-deficient T cells in unconventional 
NK T cells without GalCer reactivity [50]. We could find neither an increase in such NK1.1+ 
T cells nor did we observe any other obvious phenotypes within the NK T cell population, 
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supporting the notion that these cells are involved in the auto-inflammatory response of CD4-
cre/TR2f/f animals. However, other studies using cell ablation or MHC class I and II 
deficiencies indicated that T cells responsible for the autoimmune phenotype are found in 
both the CD4+ and CD8+ compartments [50, 230-231]. Hence, restriction of TR2 ablation to 
CD4+ T cells without affecting CD8+ T cells could only explain amelioration but not a 
complete absence of autoimmunity.  
Changes in peripheral CD4+ T cell subsets upon abrogation of TGF- 
signalling 
Even though we did not observe the anticipated autoimmune phenotype when TR2 was 
absent only from peripheral CD4+ T cells, we detected severe abnormalities within the CD4+ 
T cell compartment. Most prominently, Tefm and Treg cell numbers and percentages were 
strongly increased in the absence of TR2, with both populations being activated (CD69+) and 
cycling (BrdU+). The expansion and proliferation of T cells has been reported also in the T 
cell-specific constitutive models of absent TGF- signalling, albeit to a much stronger extent 
than in our model [49-50, 110]. This more pronounced deregulation may actually contribute 
to or even allow the development of the autoinflammation in these models. In one DN-TR2 
strain, however, only CD8+ T cells showed loss of cell cycle control[120], possibly an effect 
of expression variegation. In studies of TR2 as well as TGF-1 deficiency the 
hyperproliferative phenotype of T cells has been attributed to increased CD122 expression 
and thus increased responsiveness to IL-2 and IL-15, cytokines involved in T cell homeostasis 
[49, 95]. In contrast to these observations we do not see in our model any increase in IL-2 
production and only a slight increase in CD122 expression (IL2R chain), making it unlikely 
that this pathway is involved in the observed loss of cell cycle control in Tefm and Treg cells. 
As described before[49-50] also in our model the introduction of a TCR transgene (MOG35-
55 specific 2D2 transgene [214]) resulted in ameliorated proliferation (data not shown) 
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suggesting that a specific TCR signal through recognition of self or environmentally present 
antigens is required for induction of the observed proliferation. 
Similar to what the others reported we observed an increase in apoptosis both in vitro and in 
vivo after abrogation of TGF- signalling in CD4+ T cells [49, 108]. The level of proapoptotic 
protein Bcl-2 was downregulated similar to what was described in CD4Cre-TR2 mice. At this 
stage we cannot show which of the CD4+ T cells subsets is the most prone to apoptosis. The 
Bcl2 level in was equally downregulated in regulatory T cells, memory or naïve cells. We 
observed a drop in the numbers of naïve T cells in the spleen and lymph nodes after two and 
four weeks p.a., which could suggested that these T cells were dying faster. However, it is 
also possible that naïve T cells acquire first effector phenotype and then undergo apoptosis. 
Upon co-transfer of tamiCD4TR2 CD45.2+ T with congenic wt cells into a lymphopenic host, 
transgenic CD4+ T cells expanded faster and to a higher extent than wt cells. The expansion of 
both co-transferred population was higher than the control CD45.2+ population and congenic 
cells. We investigated possible pathways involved in T cell proliferation. The IL-2 production 
was decreased by both more expanding populations. One of the reasons for this could be that 
these CD4+ T cells deviated from memory to an exhausted phenotype which was reported 
already in chronic infectious models [232]. 
As reported before, CD4+ T cells upon abrogation of TGF- signalling also in our model 
acquire memory phenotype and become hyperproliferative but it is unlikely that this is 
dependent on their increased responsiveness to IL-2 and IL-15. 
Regulatory T cells 
In contrast to Tefm cells which seem to have increased population sizes in both the constitutive 
and the induced models of TR deficiency, Treg cells exhibit different outcomes dependent on 
when TGF- signalling is abrogated. Previously, the almost complete absence of peripheral 
Treg cells in CD4-Cre/TR2f/f animals was taken as an evidence for a prominent role of TGF- 
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in Treg cell maintenance [49]. We, however, observed upon removal of TR2 from Treg cells an 
increase in their population size that went along with their increased proliferation. In the 
CD4-Cre/TR2f/f model Treg cells and their thymic precursors mice also showed a 
hyperproliferative phenotype [49] but in the periphery exaggerated Bim-dependent apoptosis 
resulted in the drastic reduction of Treg cell numbers [108]. Interestingly, the thymic Treg cell 
expansion seen in TR1-deficient thymocytes of 1 week old mice was dependent on IL-2 
production by mutant conventional CD4+ thymocytes [109], but also these cells fail to survive 
in the periphery. In the periphery of a DN-TR2 model the CD25+ cells were expanded as well, 
but without analysis of FoxP3 expression it remains unclear whether these cells were Treg or 
activated conventional T cells [110]. Furthermore, it cannot be excluded that the seemingly 
similar observation to our model is the result of the modified instead of absent signalling, 
because transgene expression was also initiated at the DP thymic stage [49-50]. In further 
experiments we have investigated whether mature Treg cells were still retaining their 
characteristics after removal of TR2. In contrast to data from a constitutive model [107], we 
did not see a reduction of Foxp3 levels in peripheral CD25+ cells in the absence of TR2. Also, 
expression of the Treg surface markers CTLA4 and GITR was unchanged, in contrast to 
observations in young CD4-Cre/TR2f/f mice (data not shown). Furthermore, we did not 
observe any decrease in suppressive abilities of Treg cells lacking TR2, both in vitro and in 
vivo. We excluded that a defect on TR2-deficient effector T cells precluded Treg cells from 
exerting their suppressive activity, in contrast to effector T cells expressing a dominant 
negative mutant of TR2 which were shown to be resistant to suppression by wt Treg cells in 
colitis, diabetes, or tumor models [94, 233-235]. In contrast to our findings, a DN-TR2    
transgene showed deficient suppressive abilities within its Treg cell compartment [94, 107]. 
This result may be the consequence of modified but not completely absent TR signal due to 
the dominant-negative receptor. Taken together, ablation of TGF- signalling already during 
thymic development seems to lead to intrathymic hyperproliferation of Treg cells which cannot 
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survive in the periphery. In contrast, when TR2 is removed from already established 
peripheral Treg cells, these cells keep their regulatory characteristics and undergo increased 
proliferation, thus resulting in an increased Treg population size. 
Therefore, from our observations and in consistency with other experimental data, we 
propose that TGF- functions as a control factor keeping Tefm and Treg populations at bay. 
Because it was shown that TGF-can control its own expression by an autoregulatory 
mechanism [236], we investigated TGF-1 expression in presence and absence of TR2 in the 
different CD4+ T cell sub-populations. Yet, since we did not find TGF-1 production to be 
specifically restricted to these two populations, we can rule out that a direct feedback 
mechanism for control of population sizes is at play. The control may thus include other cell 
types, such as dendritic cells, which were described to be critical for suppression of 
autoimmunity by activating matrix-bound TGF- [237]. 
The role of TGF- during differentiation of CD4+ T cells into the Th1 and 
Th2 lineages 
TGF-β was shown to be a potent inhibitor of Th1 and Th2 differentiation in vitro. Addition of 
TGF-β to predisposing conditions for Th1 and Th2 subset resulted in down-regulation of 
expression of the defining transcription factors T-bet and GATA-3, respectively [197-199, 
238-239]. In accordance, studies of mice constitutively lacking TGF-β signalling in T cells 
showed that ex vivo restimulation of TR2-deficient T cells with anti-CD3 and anti-CD28 
antibodies for 24 hours led to an increased IFNγ production [49, 197]. Enhanced Th1 
differentiation was also described in vivo in the T-cell specific gene-deficiencies for TGF-1 
and its signalling pathways [49, 95]. These effector Th1 cells were able to infiltrate organs 
and establish a highly aggressive self-reactive T cell-mediated autoimmunity. In a recent 
report, the inhibitory role of TGF-β for Th1 differentiation was further assessed, using mice 
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with a T cell-specific deficiency for the down-stream targets of TGF-β signalling Smad2 and 
Smad3. It was shown that TGF-β lost its ability to inhibit differentiation of these T cells into 
the Th1 subset [202]. 
However, in our skewing experiments in Th1 predisposing conditions we could not detect any 
differences in polarization capacities of TR2-deficient T cells to differentiate into Th1 subset 
compared to control T cells. Neither IFN expression nor T-bet expression were upregulated 
as measured by intracellular staining and ELISA. After culture the cells isolated from 
tamiCD4TR2 cells in Th2 polarization we did not observe differences in T cell numbers of 
tamiCD4TR2 or control TR2 lymphocytes expressing GATA-3 and IL-4. In the supernatants 
of the cultures though, significantly higher amounts of IL-5 were produced by tamiCD4TR2 
cells than by control T cells. The different observations of IL-4 and IL-5 production could be 
due to a differential regulation of IL-4 and IL-5 expression by GATA-3. A direct involvement 
of GATA-3 in IL-5 promoter activation has been demonstrated but it seems that IL-4 gene 
expression needs multiple factors such as c-Maf or NF-IL6, which probably act in concert 
with GATA-3 to induce gene expression [173-174, 240]. 
It has also been reported before that TGF-β has different effects on naïve and effector T cells 
in vitro [241-242]. One study showed that TGF-β could inhibit cytokine production of 
memory Th1 but not Th2 cells [243]. By use of our model, mature CD4+ T cell 
subpopulations could be sorted before the deletion of TR2 and cultured separately under 
skewing conditions. This might allow an even more detailed analysis of the TGF-β signalling 
on priming or recall responses of T cells. 
In contrast to previously published reports we did not observed after in vivo ablation of TR2 
in CD4+ T cells that they spontaneously differentiate into Th1 or Th2 cells [49, 110]. Also, the 
production of IFN was only slightly upregulated ex vivo and the expression of Th2 cytokines 
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was hardly detectable. Upon CD3/28 stimulation of un-immunized T cells also no difference 
in Th1 and Th2 cytokines could be observed as well.  
In addition to the steady-state analysis, we investigated the immune response in tamiCD4TR2 
mice and Th differentiation after immunization with the model antigen KLH in CFA. This 
immunization was reported to bias the overall immune response towards Th1 with increased 
IL-2 and IFNγ, but not IL-4 production [244]. In accordance we detected high amounts of 
IFNγ in culture supernatants of restimulated KLH-primed cells. According to reports that 
established a role for TGF-β in blocking Th1 responses [49-50, 95, 110, 197-199, 238-239], 
we would have expected an enhanced differentiation into the Th1 subset along with increased 
IFNγ and IL-2 production after immunization. The produced amounts of IFNγ and IL-2 did 
not differ between TR2-deficient and control cells after 48 or 72 h. However, by ELISPOT 
assay we observed significantly more IFNγ-producing cells among tamiCD4TR2 T cells, 
which suggested an increased differentiation of TR2-deficient into Th1 subset upon KLH 
immunization in vivo. This however would implicate that cytokine production per cell was 
reduced. In contrast to the observations made by in vitro skewing, TR2-deficient T cells 
produced significantly less of IL-4 in recall response. IL-10 production was also significantly 
reduced among TR2-deficient T cells. The expression of immunoregulatory IL-10 by T cells 
has also been shown to be dependent on TGF-β signalling [245-248]. 
The observation of reduced Th2 cytokine production in restimulated TR2-deficient T cells 
contrasts the reported role of TGF-β inhibiting Th2 differentiation and the described in vitro 
findings. To exclude mainly Th1 responses in the used in vivo setup, KLH immunization with 
a Th2 response-promoting adjuvant like Ribi [244] or Alum [249] could be performed. 
An increased number of Treg cells in tamiCD4TR2 mice could potentially inhibit CD4+ T cell 
differentiation into Th1 lineage. They might have a compensatory effect on differentiation of 
T cells by exerting their suppressive functions independent of TGF-β. By generation of mixed 
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bone marrow chimeras we wanted to dilute regulatory T cells which strongly proliferated 
upon loss of TR2. After 5 weeks post reconstitution the CD45.2+ population expanded to the 
same extend as wt CD45.1+. Thus at the end we were not able to conclude if the lower 
expression of the cytokines by tamiCD4TR2 CD4+ T cells in the chimeric mice was the 
caused by enlarged population of Treg cells or was direct effect of missing TGF signalling. 
In addition we observed that the wt CD4+ T cells in experimental mixed bone marrow 
chimeric mice produced more INF and IL-17 that CD4+ T cells in control chimeras.This 
could suggest that compensatory mechanisms exist that keeps within limits the level of certain 
cytokines. Further experiment performed with mixed bone marrow chimeras would have to be 
performed to investigate the expression of cytokines upon removal of TR2 but the transgenic 
population would have to be diluted with wt cells at least 1:10. 
In the skewing conditions towards Th1 and Th2 phenotype and after CD3 and CD28 
stimulation we also analysed the expression of another cytokine that are important for effector 
function of T cells: GM-CSF [250]. Analysis performed on day three of culture showed 
significantly more GM-CSF producers among TR2-deficient T cells than among control TR2 
cells even though Th1 skewing conditions rather inhibit the production of GM-CSF. Thus, the 
absence of TR2 in CD4+ T cells promoted GM-CSF production. Similar results were obtained 
ex vivo after analysis of tamiCD4TR2 mice without immunization. In contrast, in vivo primed 
TR2-deficient T cells produced less GM-CSF upon recall.  
In conclusion, we did not observe in our model that peripheral CD4+ T cell after abrogation of 
TR2 signalling differentiate spontaneously into Th1 or Th2 lineage and even after 
immunization the difference in cytokine production are minor.  
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The role of TGF- during differentiation of CD4+ T cells in to the Th17 
lineage 
After the description of a new IL-17 producing T helper subset (Th17), distinct from Th1 and 
Th2 subset [181-182, 251], several studies showed that TGF-β signalling was essential for 
terminal differentiation of cells into this lineage [95, 142, 185-187]. We examined the role of 
TGF- for Th17 cells differentiation in our model in vitro and in vivo. For in vitro skewing 
we used culture conditions that included TGF-β as an essential cytokine to predispose naïve T 
cells to differentiate into Th17 subset. In accordance, only a little fraction of TR2-deficient T 
cells differentiated towards the Th17 phenotype. The percentage of CD4+ T cells that 
expressed both, RORγt and IL-17 was reduced to about 10 % of control CD4+ T cells. Surface 
staining of TR2 revealed that approximately 10-15 % of T cells retain the receptor after 
tamoxifen-treatment. Thus, these TR2-proficient T cells from tamiCD4TR2 animals could 
account for the small fraction polarizing into IL-17 producers. Still, so far we cannot exclude 
that also TR2-deficient cells might have differentiated towards IL-17 producing phenotype. In 
Th17 skewing condition a higher percentage among TR2-deficient T cells expressed IFNγ 
than among control T cells. This suggests that CD4+ T cells which could not differentiate into 
the Th17 subset, polarized into the Th1 phenotype, in line with results found in a recent study 
[252]. 
In vitro studies have shown that an antibody cocktail inhibiting Th1 and Th2 differentiation 
promoted polarization of Th17 subset [187]. This suggested that TGF-β functions in Th17 
differentiation by inhibiting the differentiation of Th1 and Th2 subset. Though, in the same 
and other studies [185-186] a more active role of TGF-β was revealed as neutralizing TGF-β 
antibodies abrogated Th17 differentiation completely. Also Smad2 and 3, which are regulated 
by TGF-β signalling were shown to be essential for the development of fully functional Th17 
cells [202]. To further assess the role of TGF-β for Th17 polarization, it might be possible to 
establish other in vitro conditions for Th17 differentiation. Very recently, it was shown that 
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TGF-β could be substituted by IL-1β to induce differentiation of Th17 cells in vitro [253]. 
The strong reduction of IL-17 production was also observed after CD3/CD28 stimulation of 
not primed CD4 T cells from tamiCD4TR2 mouse.  
We investigated also the production of IL-17 in vivo. After adoptive co-transfer of 
tamiCD4T2 cells together with wt cells into lymphopenic host, the IL-17 expression by the 
transgenic population was strongly reduced in the spleen and mesenteric lymph nodes. 
Similar results were obtained after immunization mixed bone marrow chimeras with KLH. In 
experimental chimeras TR2-deficient T cells expressing RORγt and IL-17 were strongly 
reduced compared to the wild type T cell population. As described for IFNγ expressing cells, 
this might suggest a compensatory effect, which would be in accordance with published data 
that TGF-β signalling is essential for Th17 differentiation. 
TGF-β signalling during experimental autoimmune encephalomyelitis 
The studies, in which the role of TGF- in EAE was investigated, showed that the action of 
this cytokine is context-dependent and site-specific. On the one hand, administration of TGF-
β ameliorated disease [133-135] and was shown to have profound effects on remission of sick 
animals [9]. TGF-β signalling in innate immune cells was shown to be protective [139] while 
on the other hand, loss of TGF-β signalling in T cells led to a reduced EAE susceptibility [95, 
142]. Production of TGF-β by glial cells was reported to promote CNS infiltration of 
pathogenic T cells [254-255]. By use of our tamoxifen-inducible model we thus wanted to 
investigate the role of TGF-β signalling in mature CD4+ T cells during EAE. This question 
was previously approached by use of models for T cell-specific abrogation of TGF-β 
signalling. In the CD4-dnTGF-βRII model, animals were less susceptible to EAE which was 
only connected by the authors with a reduced Th17 development [187]. In accordance, local 
administration of neutralizing TGF-β antibodies inhibited disease development in wild type 
animals, which was proposed to prevent Th17 differentiation. T cell-produced TGF-β also 
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seemed to be essential for the development of encephalitogenic Th17 cells [95]. Animals that 
lacked T cell-produced TGF-β showed only mild clinical symptoms. However, expansion of 
primed Th17 cells in presence of TGF-β reduced their encephalitogenicity in an adoptive 
transfer EAE model [143]. 
Ours experiments with tamiCD4TR2 mice revealed that animals which had been actively 
immunized with MOG35-55 peptide were as susceptible to EAE as wild type animals. Because 
tamoxifen treatment showed a considerable side-effect and reduced disease severity, a new 
setup was established in order to elucidate the role of TGF-β signalling on development of the 
disease. Cells from tamiCD4TR2 2d2 mice were transferred into RAG1-/- animals followed by 
active immunization with MOG peptide. All recipients of 2d2 tamiCD4TR2 and 2d2 control 
TR2 cells developed a severe terminal disease. No differences between recipients of 2d2 
tamiCD4TR2 cells and recipients of 2d2 control TR2 cells was in the course of the disease. 
Thus, TR2-deficient 2d2 T cells were able to establish EAE to a similar degree and incidence 
as wild type 2d2 cells. However, as the severity of disease in this model increased very fast, 
this strong outcome may have masked minor differences in disease course upon ablation of 
TR2. Additionally in 2d2 TCR transgenic mice the population of regulatory T cells is reduced 
which make it even more difficult to elucidate their role in EAE after abrogation of TGF- 
signalling. To better investigate the role of TGF- signalling during EAE different 
experimental setups will have to be tested in which tamoxifen treatment did not interfere with 
immunizations and disease course is milder.  
General implications of results in the context of technology and 
knowledge 
Taken together, our study suggests that several misconceptions about TGF- function in 
peripheral lymphatic organs are the result of gene ablation during T cell development. By 
restricting the genetic defect (TR2-deficiency) to mature T cells we could show clearly that 
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TGF- signalling is not essential for the suppression of autoimmunity and the maintenance of 
a functional Treg cell pool. Instead it is required for inhibition of overt proliferative activity of 
Treg and Tefm cells. In addition, we could not observe any role in IL-2 signalling and IL-2 
production. Furthermore tamiCD4+ T cells did not acquire spontaneously a Th1 phenotype 
described before.  Thus, TGF-1 remains a cytokine with critical function in the regulation of 
T cells, yet its role in peripheral tolerance seems to have been somewhat overinterpreted in 
the past. 
Our new tamoxifen-inducible CD4-CreERt2 strain is the first mouse model which allows 
efficiently inducing or depleting the gene of interest solely in CD4+ T cells. Thus this 
transgenic mouse can be a very useful tool in many immunological projects. 
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ABBREVIATIONS 
 
 ABBREVIATIONS 
APC 
CD 
CNS 
cTEC 
Antigen presenting cell 
Cluster of differentiation 
Central nervous system 
Cortical thymic epithelial cell 
DN Double negative thymocyte 
DP 
DC 
EAE 
IBD 
Double positive thymocyte 
Dendritic cell 
Experimental autoimmune encephalomyelitis 
Inflammatory bowel disease  
iCD4TR2 CD4-CreERt2/TGFbRII f/f 
KLH Keyhole limpet hemocyanin 
LN 
MHC 
Lymph node 
Major histocompatibility complex 
MOG 
MS 
Myelin oligodendrocyte glycoprotein 
Multiple sclerosis 
p.a. 
PMA 
SLE 
SP 
Post application 
Phorbol 12-myristate 13-acetate 
Systemic lupus erythematosus 
Single positive thymocyte 
tamiCD4TR2 
TCR 
Tamoxifen-treated CD4-CreERt2/TGFbRII f/f 
T cell receptor 
Th T helper 
Tefm Effector memory T cells 
Tn naïve T ce 
Treg Regulatory T cells 
nTreg Natural regulatory T cells 
TR1 TGF-RI, transforming growth factor receptor I 
TR2 TGF-RI, transforming growth factor receptor II 
wt Wild-type 
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